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Abstract 
Title: Market Research within the Pharmaceutical Industry –        
A Case study of SPAGO Imaging AB 
Author: Angelica Rönnholm 
Supervisors:  Ingela Elofsson, Department of Production Management, 
Lund Institute of Technology 
 Oskar Axelsson, Chief Technical Officer, SPAGO Imaging AB 
Problem definition:  SPAGO Imaging AB is developing a new contrast agent for 
Magnetic Resonance Imaging (MRI). In approximately 5 
years, the product will be launched on the market. The 
company is therefore about to look for investors to fund the 
development and growth. To gain investors interest, a 
clearly defined market for this sort of contrast agent is 
required. 
Purpose:  The purpose of this thesis is to analyze the market of 
SPAGO Imaging AB´s contrast agent in the field of breast 
cancer. 
Methodology: The approach of the theses was a survey study because the 
interest was to gather basic knowledge from many fields. 
The study is based primarily on secondary data, gathered 
through books, scientific papers and various websites. The 
secondary data was complemented with primary data, 
collected through personal interview and internet surveys 
with three radiologists. Most of the collected data is 
qualitative in nature. 
Conclusions: Breast cancer is the most frequency diagnosed malignancy 
in women. The most widely used screening test to detect 
breast cancer is mammography, but mammography 
involves ionizing radiation that can produce adverse health 
effects and the sensitivity of the test is limited (79%).  
Magnetic Resonance Imaging is a valuable complementary 
modality to conventional screening methods. The strength 
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of the MRI technology is the high sensitivity (92.5%). MRI 
also uses radio-frequency waves, which is non-ionizing 
energy and considered safe. Nevertheless, breast MRI has 
played a limited role in cancer detection. It is probably due 
to a combination of a low specificity (72.4%) and the 
significantly higher cost.  
The new contrast agent, developed by SPAGO Imaging AB, 
will most likely give a higher specificity and a higher 
sensitivity. The product will however not change the fact 
that the MRI is not appropriate for general screening. The 
reason for that is the high cost together with the long 
waiting time after the administration of the contrast agent.  
The screening has, however, become more individual-based 
and women with increased risk for developing breast 
cancer need a more sensitive screening tool. The contrast 
agent of SPAGO Imaging AB is therefore suitable for 
screening women with high risk of developing breast 
cancer.  
Diagnostic tests are used to classifying the tumors and to 
gather more information about the cancer. For the purpose 
of determining the size and location of the tumors the most 
common methods are mammography and sonography.  
However, the high soft tissue contrast and three-
dimensional format of MRI allows anatomic structures of 
the breast to be viewed in greater detail. Why the MRI 
technique isn’t used to a higher extent for diagnostic 
purposes probably depends on a combination of a lack of 
availability and the risk of overestimating the extent of 
disease. SPAGO Imaging AB´s contrast agent will most likely 
give a better contrast so the diagnostic area is also a 
potential segment. 
Keywords: Market Research, Contrast Agent, Magnetic Resonance 
Imaging, Product Development 
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1. Introduction 
 
In chapter one the reader is first introduced to the company SPAGO Imaging AB, 
followed by a background and problem discussion. Second, the purpose of the 
master thesis is being established as well as the targeted group. Finally, a brief 
overview is given of the structure of this report. 
 
1.1 Company Presentation 
“Market Research within the Pharmaceutical Industry - A Case study of SPAGO 
Imaging AB” is the title of this master thesis which was written in cooperation 
with the company SPAGO Imaging AB. SPAGO Imaging AB is a small R&D company 
located in Lund, Sweden. The company develops a nanoparticle-based contrast 
agent for Magnetic Resonance Imaging (MRI) with applications in tumor 
diagnostics and the cardio-vascular field.1  
1.1.1 Vision 
The long-term vision of SPAGO Imaging AB is the following: 
 
”Be a world leading translational R&D company for in-vivo diagnostics supplying 
partners with strong projects for commercialization.”2 
1.1.2 History 
SPAGO Imaging AB is a relatively new company, founded in the year of 2007 in 
Linköping, Sweden. The business idea is based on research about nanoparticle-
based contrast agents as part of a project called Spago Enhanced MRI (formerly 
known as MRI Boost).3 
 
Dr. Kajsa Uvdal, a physicist at Linköping University, managed to create 
nanoparticles of Gadolinium oxide. To get a medical application of the 
nanoparticles, Kajsa Uvdal turned to Dr. Maria Engström, a researcher at the 
Center for Medical Image Science and Visualization (CMIV) at the University 
Hospital in Linköping. Maria Engström was at the time working with a technique 
                                                             
1 Homepage of SPAGO Imaging AB, Home [Online] 
2 Axelsson, O., personal communication, August 17, 2009 
3 Axelsson, O., personal communication, August 17, 2009 
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called Magnetic Resonance Imaging, in order to take pictures of the body’s 
interior.4 
 
Magnetic Resonance Imaging uses a powerful magnetic field, radio frequency 
pulses and a computer to produce three-dimensional images of the body's 
interior.5 For better contrast, patients get injected with a contrast agent. These 
agents improve the contrast of MRI images by increasing the brightness in various 
parts of the body where the agent resides. The most common contrast media 
used today is made up of individual atoms of gadolinium.6 
The contact between Maria Engström and Kajsa Uvdal led to the idea that the 
newly developed nanoparticles could be used as a contrast agent to enhance 
signals in the MRI scanner. The promising results from the studies prompted the 
inventors to submit two patents, which later were licensed to Accelerator Nordic 
AB (then Accelerator i Linköping AB).7 
 
After some small scale efforts to bring the project forward in an academic setting, 
a decision was made to form a company and employ qualified staff to bring the 
project forward to a state that could either attract licensees or investors. In March 
2007 Rodrigo Petoral, a former PhD student of Uvdal, was hired and a few months 
later Oskar Axelsson, with a background in MR contrast- and nanoparticle 
research from GE-healthcare, joined.  
 
The company is, since January 2008, located in the Ideon Bioincubator at BMC, 
Lund, and has in the current situation three fulltime and one halftime employees.8 
1.1.3 Organization 
SPAGO Imaging AB is a subsidiary of Accelerator Nordic AB, located in Stockholm. 
Accelerator Nordic AB owns a number of companies within the area of Life 
Sciences. Among the companies are, in addition to SPAGO Imaging AB, 
PledPharma AB, which develops pharmaceutical applications, Synthetic MR AB, 
which develops software for time-saving synthetic MRI, OptoQ AB which markets 
                                                             
4 Engelmark Cederborg, S., 2006, Partiklar med potential [Online]  
5 Homepage of RadiologyInfo, MRI of the Body (Chest, Abdomen, Pelvis) [Online]  
6 Axelsson, O., personal communication, September 8, 2009 
7 Axelsson, O., personal communication, September 8, 2009 
8 Axelsson, O., personal communication, September 8, 2009 
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and sells systems and technology platforms for patient monitoring and Optovent 
AB which develops and commercializes research-based innovations.9 
 
Figure 1.1 – The organization of Accelerator Nordic AB.10 
1.2 Background and Problem Discussion 
SPAGO Imaging AB is currently about to enter a formal preclinical phase where 
the stability of the particles has been secured and verified. There is an estimated 
five years until the contrast agent will be launched on the market.11 At this 
important stage of development the company is facing a major business 
challenge: to move from a research company to a company that have a 
commercial product out on the market. Therefore, the company is about to look 
for investors to fund the development and growth. To get investors interested it 
requires a clearly defined market for this sort of contrast agent. 
The product of SPAGO Imaging AB is an MRI contrast agent, meaning that the 
contrast agent can only be used together with the Magnetic Resonance Imaging 
technology. MRI is a relatively new technology which has completely 
revolutionized the field of medical imaging. The technique is used for detecting 
abnormalities or lesions in most parts of the body and is administered to patients 
suffering from the following:12 
 Cancer 
 Degenerative diseases  
 Inflammation or Infection  
 Strokes  
 Musculoskeletal disorders  
                                                             
9 Homepage of Accelerator Nordic AB, Om Accelerator [Online] 
10 Axelsson, O. (oskar.axelsson@spagoimaging.se), 3 November 2009 [e-mail]  
11 Axelsson, O., personal communication, September 8, 2009 
12 Homepage of University of Windsor, Applications of MRI [Online]  
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The selected area for this study was cancer because it is a widespread disease, 
with more than eleven million people diagnosed with it every year. The area has 
also several applications for the MRI technology and there are indications that 
progress in the MRI field may give medical benefits. 
Cancer is, however, not a single disease but a group of diseases of which there are 
over a hundred types.13 It has therefore, due to time constraints, been necessary 
to limit the scope of the study to only one form of cancer, namely breast cancer.  
Breast cancer is the second most common cancer worldwide, with over one 
million new cases each year.14 Death rates from breast cancer have been steadily 
decreasing due to a combination of early detection and improved treatment. 
Nevertheless, half of all patients diagnosed with breast cancer will die from the 
disease.15 The greatest potential for a reduction in mortality is earlier detection 
and more accurate diagnoses, so new, better methods are urgently needed. 
Breast cancer is therefore a very interesting market field for SPAGO's contrast 
agent. 
1.3 Purpose of the Thesis 
The main purpose of this thesis is to analyze the market of SPAGO Imaging AB´s 
product in the field of breast cancer. This requires separate analysis of the MRI 
market and SPAGO´s contrast agent. The study will therefore include both an 
analysis of the current methods to identify breast cancer, as well as an analysis of 
the properties of SPAGO´s product.  
1.4 Target Group 
This master thesis is written for two separate targeted groups; the management 
of SPAGO Imaging AB and senior students with a business or engineering 
background.  
 
 
 
 
                                                             
13 Zebrowski, M., 2007, p. 19 
14 Center, M., Garcia, M., Hao, Y., Jemal, A., Siegel, R., Thun, M.  & Ward, E., 2007, p. 3 
15 Bruening, W., Kostinsky, H., Launders, J., Pinkney, N., Schoelles, K. & Turkelson, C., 2006, p. 5 
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1.5 Structure of the Thesis 
This thesis is structured in seven main chapters. Following is an overview of what 
each chapter in short offers: 
 
Chapter 1 – Introduction 
In chapter one the reader is first introduced to the company SPAGO Imaging AB, 
followed by a background and problem discussion. Second, the purpose of the 
master thesis is being established as well as the targeted group. Finally, a brief 
overview is given of the structure of this report. 
Chapter 2 – Methodology 
Chapter two serves as guidance for the reader in order to explain how the data 
have been managed and which methodological approaches have been utilized to 
penetrate the issues covered in this thesis. Different study approaches, as well as 
different data collection methods, are discussed. This is followed by a description 
of the collection process of both primary and secondary data and the section ends 
with a discussion of validity, reliability and how criticism of the sources have been 
handled. 
Chapter 3 – Theory 
In chapter three the theory used for the master thesis is presented. The theory 
includes different definitions relevant to the thesis, as well as tools and methods 
used in the analysis. 
Chapter 4 – Empirics: Cancer and Methods for Cancer Detection  
Chapter four contains information about cancer, breast cancer, as well as current 
techniques to detect breast cancer. 
Chapter 5 – Analysis of the MRI technology 
Chapter five contains an analysis of the MRI technology. The advantages and 
disadvantages, as well as possible areas for improvement, of the technology are 
discussed. 
Chapter 6 – Empirics and Analysis of SPAGO´s contrast agent 
Chapter six contains a description of SPAGO´s contrast agent and a brief overview 
of the market of MRI and the existing contrast agents. The chapter also includes a 
SWOT analysis of SPAGO´s product. 
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Chapter 7 – Summary and Reflections  
Chapter seven summarizes the impressions from the empirics and the analysis. 
The most important findings are brought together and form the basis of the 
presented recommendations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
2. Methodology 
 
Chapter two serves as guidance for the reader in order to explain how the data 
have been managed and which methodological approaches have been utilized to 
penetrate the issues covered in this thesis. Different study approaches, as well as 
different data collection methods, are discussed. This is followed by a description 
of the collection process of both primary and secondary data and the section ends 
with a discussion of validity, reliability and how criticism of the sources have been 
handled. 
 
2.1 Methodological Approach  
The methodology is the overall approach used throughout the study; how to go 
from the initial formulation of the objectives to the final results of the analysis.16 
What methodology should be chosen depends on the purpose of the study and 
the amount of available knowledge in the specific area.17  
The purpose of an investigation may be of four types: descriptive, explorative, 
explaining or predictive. 
Descriptive – A descriptive approach is used when basic knowledge already exists. 
The aim is to strengthen the relationship without explaining the context in the 
field.18 The focus is to describe, not to understand or interpret something.19 
Explorative – An exploratory approach is used when there is little available 
knowledge in the field. The aim is to obtain as much knowledge and 
understanding as possible about the specific area.20  
Explaining – An explaining approach investigates causality within an area, how 
various factors are interrelated and what the outcome of this is.21  
                                                             
16
 Höst, M., Regnell, B., & Runeson, P., 2006, p. 29 
17 Höst, M., Regnell, B., & Runeson, P., 2006, p. 29 
18 Lekvall, P. & Wahlbin, C., 2001, p. 197 
19 Andersen, I., 1998, p. 18 
20 Davidson, B. & Patel, R., 2003, p. 12 
21 Lekvall, P. & Wahlbin, C., 2001, p. 197 
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Predictive – A predictive approach is used for studies that provide forecasts of 
what would probably happen if certain specified conditions exist.22 
The type of purpose which, according to the above definitions, is best suited to 
this study is the explorative approach. The purpose of an exploratory survey is to 
gather as much knowledge as possible about a specific problem area and that 
conform with the intention of this thesis.23  
In a scientific work, there are two different strategies for producing knowledge; 
deduction or induction. If the study is based on empirical data and the conclusions 
are drawn after the data is collected and analyzed, the study is inductive.24 
Induction is sometimes also referred to as “the road of discovery” for the reason 
that the purpose is to form theories using the actual knowledge.25  
If the study is based on a theory, which is then verified or rejected by the 
collected data, the orientation is said to be deductive.26 In a deductive approach 
the conclusions are drawn from the existing theory and therefore called “the road 
of proof”.27  
 
Figure 2.1 – Induction and deduction.28 
 
 
                                                             
22 Lekvall, P. & Wahlbin, C., 2001, pp. 197-198 
23
 Davidson, B. & Patel, R., 2003, p. 12 
24 Johannessen, A. & Tufte, P., 2003, p. 35 
25 Andersen, I., 1998, p. 29 
26 Johannessen, A. & Tufte, P., 2003, p. 35 
27 Andersen, I., 1998, p. 29 
28 Perolle, J., 1998 (redrawn) [e-book]  
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The starting point of this essay was the collected data, presented in Chapter 3, 
and then, from the collected data, creating a picture of the MRI market and the 
market for SPAGO's contrast agent. The thesis can therefore said to have an 
inductive approach.  
 
The main criticism of an inductive study is that it can be difficult to draw general 
conclusions, since the outcome depends on the limited amount of collected 
data.29  However, the purpose of this thesis is only to analyze the market of 
SPAGO's contrast agent and not to draw general conclusions about all actors in 
the MRI contrast agent industry.  
2.2 Study Approach 
The approach of the study has to do with its basic technical design; how we 
technically should proceed to draw the desired conclusions.30 There are three 
main approaches to choose from: 
Case study - In a case study just one individual or a small number of cases are 
analyzed. The interest is directed towards detailed and often in-depth 
descriptions. There is no concern in comparing the survey items with each other 
or to make any generalizations about an underlying population.31 
Survey - Surveys are research strategies where a large number of cases are 
analyzed in width. A survey research is often characterized by the interest to 
analyze and draw conclusions about an underlying target population, to which the 
study units is assumed to represent. The reality is observed as it is, whiteout 
trying to affect it.32 
Experimental study - An experimental study is also a research strategy where a 
large number of cases are analyzed in width, but unlike the survey approach a 
researcher in an experimental study actively manipulate the reality so the 
investigated factors become clearly highlighted.33 
                                                             
29 Wallén, G., 1996, p. 89 
30 Lekvall, P. & Wahlbin, C., 2001, p. 209 
31 Lekvall, P. & Wahlbin, C., 2001, pp. 215-216 
32 Lekvall, P. & Wahlbin, C., 2001, pp. 216-217 
33 Lekvall, P. & Wahlbin, C., 2001, p. 210 
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The chosen research strategy for this thesis was the survey approach because of 
the purpose; to analyze and describe the market of MRI and contrast agents. To 
conduct that, a broad coverage was necessary.  
2.3 Data Collection 
2.3.1 Quantitative and Qualitative Data 
The research can be based on two different kinds of data: quantitative or 
qualitative. Quantitative data are expressed in numerical form and often analyzed 
using some form of mathematical-statistical methods of calculation.34 Qualitative 
data are instead information gathered from qualitative interviews or interpretive 
analysis. That is data that cannot meaningfully be quantified, i.e. expressed in 
numerical form.35  
A qualitative approach is used to give the researcher a deeper understanding of 
the problem area or to gain novel understanding in a specific field. Since the 
purpose of this thesis is to analyze the market of MRI contrast agents, a 
qualitative research is adequate and therefore also chosen.  
2.3.2 Primary and Secondary Data 
The collected data can be divided in two groups, primary or secondary data. 
Secondary data is information that is already collected and compiled for another 
purpose. Primary data is information that the researcher collects himself from the 
original source.36  
It is usually much cheaper and less time consuming to collect secondary data 
compared to gathering own primary data. Secondary data can also be helpful in 
the design of the subsequent primary research and can provide a baseline with 
which the collected primary data results can be compared to. Therefore, it is 
always wise to begin any research activity with a review of the secondary data.37 A 
study based solely on secondary data is called a desk study.38 
In the case of primary data, there are four common methods for collecting it: by 
written questionnaires, face-to-face interviews, telephone interviews or Internet 
surveys.  
                                                             
34 Lekvall, P. & Wahlbin, C., 2001, p. 210 
35 Lekvall, P. & Wahlbin, C., 2001, p. 210 
36 Lekvall, P. & Wahlbin, C., 2001, p. 80 
37 Lekvall, P. & Wahlbin, C., 2001, p. 212 
38 Andberg, L. & Eliasson, B., 2005, p. 32 
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Written questionnaires – In a written questionnaire the questions are being asked 
and answered in writing form on a paper that is distributed and returned between 
the investigator and the respondent, without the intermediary of an interviewer. 
The big advantage of the written questionnaires is the low cost per unit. The 
method is therefore suitable for studies with large samples. If the questionnaires 
are sent by post it is often become time-consuming. There is also a risk of large 
losses and the control over the interview situation is weak, i.e. cannot control the 
order in which questions are answered in or who is actually answering the 
questions.39  
Face-to-face interviews – In face-to-face interviews are the questions posed and 
answered verbally in a personal meeting between the interviewer and the 
respondent. The big advantage of the personal interview is the possibilities to 
make different types of questions.40 Another major advantage of face-to-face 
interviews is that response rates are generally very high.41 The major drawbacks 
are that they are more expensive than the other methods and that it practically 
can be difficult to implement.42 The presence of an interviewer can also cause 
bias, i.e. socially desirable answers, and lead to misleading information.43 
 
Telephone interviews – In a telephone interview are the questions posed by an 
interviewer and answered verbally during a telephone conversation with the 
respondent.44 The properties of the telephone interviews are something between 
the face-to-face interview and the written questionnaires. They generally have a 
higher response rate than the written questionnaires but lower that the face-to-
face interviews. The cost is usually less than face-to-face but higher than for the 
written questionnaires.45 
Internet surveys - The questions are posed in written form on the internet, by e-
mail or direct on a homepage. There is no interviewer as a link between the 
investigator and the respondent. The advantages are the low cost per unit and the 
rapidity of the method. It is also possible to have a more pedagogical layout in the 
                                                             
39 Lekvall, P. & Wahlbin, C., 2001, p. 262 
40
 Lekvall, P. & Wahlbin, C., 2001, p. 265 
41 Jobber, D., 2007, p. 250 
42 Jobber, D., 2007, p. 251 
43 Jobber, D., 2007, p. 251 
44 Lekvall, P. & Wahlbin, C., 2001, p. 266 
45 Jobber, D., 2007, p. 251 
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form of illustrations, animations and sounds. The disadvantage is a risk of large 
losses and a weak control over the interview situation.46  
In order to gain novel understanding about the MRI market, a thorough desk 
study was conducted. Information from books, research articles and various 
websites was gathered. Research articles were found via Lund University Library 
database ELIN (Electronic Library Information Navigator). Extensive searches in 
various databases like the WorldWebScience, Public Library of Science (PLoS) and 
the PubMed database was also conducted. Lovisa, a literature catalog provided by 
the Lund University Library, was also used to find relevant literature.  
 
The secondary data was also complemented with primary data. The primary data 
was collected by a face-to-face interview with one radiologist and internet surveys 
(via e-mail) with two radiologists. The face-to-face interview was chosen because 
of the ability for dynamics during the questioning and for the reason that the 
interview could be done fairly extensive. Since the other two radiologists could 
not attend a personal interview, internet surveys (via e-mail) were chosen.  
 
The personal interview was of a less structured character using mostly open-
ended questions, so that the respondent freely could describe the MRI market in 
order to receive as much information as possible. The questionnaire used for the 
internet surveys is presented in Appendix A. 
2.3.3 Sampling Techniques 
There are two different groups of sampling techniques, probability sampling and 
non-probability sampling. The difference between them is that probability 
sampling involves random selection and non-probability sampling does not. The 
probability of getting any particular sample can therefore only be quantitatively 
calculated when using a probability sampling technique.47 
Probability sampling is mostly used within quantitative studies. Researchers who 
conduct qualitative studies find it difficult to adhere to the principles and 
procedures of probability sampling for selecting people or events. It is therefore 
common to use non-probability sampling techniques when conducting a 
qualitative research.48  
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The respondents of this study were chosen in collaboration with my supervisor at 
SPAGO Imaging AB, Oskar Axelsson and with the help of the first respondent 
Christer Lundahl. Because no random selection took place, the sampling method 
can be classified as a non-probability sampling technique.  
2.4 Criticism 
Two concepts are used to measure the credibility of a study; validity and 
reliability.49  The aim should be to achieve as high validity and reliability as 
possible. However, the credibility is always balanced against the resources 
required for the design of the study.50 
2.4.1 Reliability 
The term reliability can be said to express the method's ability to resist influence 
from various coincidences.51 With good reliability means that similar results could 
be obtained if the experiment was repeated.52  
 
The reliability of a study can be increased through the use of control questions in 
surveys and interview and through the use of multiple perspectives or several 
types of data, i.e. triangulation.53   
 
In this study, the striving has been to combine different types of data. Information 
from scientific reports, books, market statistics and personal interviews has 
therefore been combined in order to increase the reliability.  
2.4.2 Validity 
The definition of validity is the instrument's ability to measure what was intended 
to measure. Validity can be divided into two aspects: internal validity and external 
validity. Internal validity refers to the conformance between the concept and its 
operationalization. With operationalization mean how to transfer the theoretical 
ideas in the form of concepts and models to empirical observations. External 
validity has to do with the correlation between the measured value that is 
obtained, when using an operational definition, and the reality.54  
 
                                                             
49
 Björklund, M. & Paulsson, U., 2003, p. 60 
50 Björklund, M. & Paulsson, U., 2003, p. 59 
51 Lekvall, P. & Wahlbin, C., 2001, p. 304 
52 Lekvall, P. & Wahlbin, C., 2001, p. 306 
53 Björklund, M. & Paulsson, U., 2003, p. 60 
54 Eriksson, L. & Wiedersheim-Paul, F., 2006, pp. 60-61 
14 
 
When using questionnaires or interviews, validity can be increased through the 
formulation of clear, non-biased questions.55 The use of triangulation can also 
increase the validity.56 Another thing that can increase the validity is respondent 
validation: the researcher can present the collected data in aggregate form for the 
persons who have been interviewed. That is a way to ensure that the participants 
are correctly understood.57   
 
The striving has been to formulate clear, non-biased questions for the purpose to 
get a high validity. The respondents had also access to the report to examine if the 
interpretation of their contribution was correct, i.e. respondent validation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
55 Björklund, M. & Paulsson, U., 2003, p. 60 
56 Björklund, M. & Paulsson, U., 2003, p. 60 
57 Robson, C., 2002, p. 42 
15 
 
3. Theory 
 
In chapter three the theory used for the master thesis is presented. The theory 
includes different definitions relevant to the thesis, as well as tools and methods 
used in the analysis. 
 
3.1 Definitions 
The purpose of this thesis is to analyze the market of SPAGO Imaging AB´s 
product, but before the concept of a market research is discussed it is important 
to clarify the word market. Originally, the term market stood for a place where 
buyers and sellers gathered to exchange their goods, such as a village square.58 
Today, the term often refer to a collection of buyers in a particular product class.59 
The definition of a market is: 
“A market is the set of actual and potential buyers of a product. These buyers 
share a particular need or want that can be satisfied through exchanges and 
relationships.”60 
There are geographic markets which relate to customers within a specific 
geographic area, such as the Swedish market. The market can also be defined as 
the application area for a particular product.61  
 
In literature there are two different explanations for how a market is created. 
According to Armstrong & Kotler (2006) customers already exist; they do not need 
to be created. The company's mission is therefore to try to get, as many as 
possible of those, to buy the product.62 This is sometimes called a top-down 
process because the customer is selected by the company.63 According to other 
authors, such as Sarasvathy, the market is created by the company.64 This means 
                                                             
58 Hague, P., 2002, p. 4 
59
 Armstrong, G., Kotler, P., Saunders, J. & Wong, V., 2005, p. 11 
60 Armstrong, G., Kotler, P., Saunders, J. & Wong, V., 2005, p. 11 
61 Olsson, J. & Skärvad, P.-H., 2003, p. 241 
62 Armstrong, G. & Kotler, P., 2006, p. 40 
63 Stokes, D., 2000, p. 51 
64 Sarasvathy, S., 2001, p. 244 
16 
 
that some customer group will be selected by the company and other groups will 
be ignored; it becomes a so-called bottom-up process.65 
Regardless of the view to how the market is created, the company must try to 
understand the customers and their needs. This is done by analyzing the market, 
i.e. by conduct a market research.66 
A market research is any organized effort to gather information about markets or 
customers. It is an important component of business strategy.67 The role of 
market research is simply to strive to coordinate and concentrate a firm's total 
resources to those parts of the market where the greatest likelihood of success 
are.68 
As mentioned earlier, the market consists of both actual and potential buyers. 
These buyers differ in one or more ways. They can have different needs, 
resources, locations and buying attitudes.69 Companies cannot satisfy all these 
different consumers, there a too many kinds of them with too many kinds of 
needs. Consequently, companies use market segmentation to divide the total 
market.70 Market segmentation is defined as follow: 
 
“(…) the identification of individuals or organizations with similar characteristics 
that have significant implications for the determination of marketing strategy”.71 
 
Market segmentation, then, consists of dividing a diverse market into a number of 
smaller, more similar, sub-markets. The objective is to identify groups of 
consumers with similar requirements so that they can be served effectively while 
being of a sufficient size for the product or service to be supplied efficiently.72 A 
market can be segmented in a variety of ways. It can be geographical factors, such 
as different regions or climate, demographical factors, like age or gender, psycho 
graphical factors, such as lifestyle and personality, or behavioral factors, for 
example purchase occasion or benefit sought.73 Each segment should consist of 
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customers with similar needs and behavior and thereby differentiate themselves 
from other individuals or groups of customers.74  
 
The company should then evaluate the attractiveness of each market segment 
and selecting one or more segments to enter, this is called market targeting, i.e. 
to practice segmentation.75 An organization evaluates its strengths relative to the 
competition and considers how many segments it can serve effectively.76 The 
company should select those segments where they can offer the most.77 
3.2 SWOT Analysis 
To evaluate the product of SPAGO Imaging AB, a SWOT analysis has been 
conducted. A SWOT analysis is a structured approach to evaluating the strategic 
position of a business by identifying its strengths (S), weaknesses (W), 
opportunities (O) and threats (T).The aim is to identify the internal strengths and 
weaknesses of an organization and to consider if they are adequate to handle the 
external opportunities and threats that exist around the company.78 If the analysis 
is used correctly it can help the manager anticipate important developments that 
can have an impact on the company.79  
 
  
Helpful 
 
 
Harmful 
 
 
Internal 
 
Strengths 
 
Weaknesses 
 
External 
 
Opportunities 
 
Threats 
Table 3.1 – Strengths, weaknesses, opportunities and threats (SWOT) analysis. 
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When evaluating strengths and weaknesses, only those resources or capabilities 
that a customer would value should be included.80 The strengths and weaknesses 
in the analysis should be based on facts and be relative, not absolute.81  
The opportunities and threats that are listed should be events or trends outside 
the business that have implications for performance.82 Not all threats call for the 
same attention. It is important to assess the likelihood of each threat and the 
potential damage each case could cause and then focus on the most probable and 
harmful threats and prepare plans to meet them.83 Opportunities often involves 
risks, so when evaluating opportunities, the manager must decide whether the 
expected returns justify these risks.84 
3.3 Product Life Cycle 
The product life cycle (PLC) is a curve which breaks down product sales into four 
stages. The stages are introduction, growth, maturity and decline, see Figure 3.1.85 
The curve is shaped like an S and reflects a process of slow adoption in the early 
stages, followed by a rapid acceleration and ending with a plateau representing 
the limited demand.86 
The product life cycle concept is useful for management in several ways; one way 
is to conceptualize different general approaches to developing core strategies. It is 
a quite flexible tool and can be applied to both brands and product lines.87 Each 
stage represents specific challenges, therefore can particular strategies be found 
on each stage.88 
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Figure 3.1 – The Product Life Cycle.89 
Introduction - When a product is first introduced on the market both the growth 
rate and the size of the market is low.90 The introduction phase is also 
characterized by few (or no) competitors. The sales volume increases slowly due 
to the small number of firms marketing the product and the reluctance of the 
customers.91  
The objective for a product in the introduction stage is to build sales by expanding 
the market for the product. It is important to create product awareness so that 
more customers will become familiar with the benefits of the product. The 
product is likely to be non-differentiated to appeal to different customer groups.92  
There are two well-known strategy options in the introduction phase: skimming or 
penetrating. The skimming strategy assumes a product feature-based advantage 
that allows the company to enter the market with a high price. Target customers 
are the least price sensitive. The company should choose a skimming strategy 
when the cost structure of the product is largely variable cost, which is usually the 
case with manufactured goods. The skimming strategy is also the best choice 
when high entry barriers exist, because high prices make the market very 
attractive to potential competitors. A penetration strategy is just the opposite: 
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the company uses a low-price strategy to attempts to get as many customers as 
quickly as possible. A penetration strategy should be chosen if the fixed costs are 
high or the product is assumed to be short-lived.93 
Growth - Growth is a stage characterized by a period of faster sales and profit 
growth. The growth is fuelled by rapid market acceptance and sometimes also 
repeat purchasing. Profits may begin to decline in the end of the stage as new 
rivals enter the market, attracted by the high profit potential. As customers 
become more knowledgeable about the available products, this puts pressure on 
the prices.94  
The objective during the growth phase is to both increase sales and gain higher 
market share. To accomplish this task the product is often redesigned to create 
differentiation.95  Another key focus should be to try hold on to the distribution 
channels.96 
The starting point of the growth phase is sometimes referred to as the tipping 
point. In the tipping point the demand for the product suddenly takes off, with 
explosive growth. There is therefore very important to try to anticipate when the 
tipping point will occur, otherwise it leads to missed sales and easy opportunities 
for competitors.97 
Maturity - The maturity stage is a period where saturation occurs. The market is 
not growing and the existing competitors are fighting for market share.98  
The objective should be to hold on to profits by protecting the existing market 
share rather than try to increase the sales.99 There is a need for effective brand 
building as brand leaders are in the strongest position to resist the pressure on 
profit margins.100 
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Decline - The last stage is decline, where the demand for the product is reduced 
so the sales and profits fall.101  
The conventional strategies in the decline stage are either harvest or divest. The 
harvest strategy would result in higher prices in an effort to boost profit margins. 
The divestment strategy may take the form of selling products to other companies 
or simply product elimination.102 There is also a strategy to try to be the last in the 
market. By being last, the product can have monopoly to the few customers left 
and to charge these customers with high prices.103 
3.4 The Ansoff Product/Market Growth Matrix 
To better understand the challenges witch the product faces, the Ansoff product 
/market growth matrix is a useful tool. The Ansoff product/market growth matrix 
provides a simple way of generating four basic alternative directions for strategic 
development, see Figure 3.2. The matrix considers four growth options: market 
penetration, product development, market development and diversification.104 
 
Figure 3.2 – The Ansoff product /market growth matrix. 
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Market penetration - Market penetration is a strategy where existing product is 
launched on an already existing market. The aim is to gain market share.105 The 
most basic method of gaining market penetration is by winning competitors´ 
customers. Another way of gaining market penetration is to buy the 
competitors.106  
Companies that choose the market penetrating strategy may face legal constrains 
because greater market share can raise concerns from official competition 
regulators.107 A market penetration strategy can also exacerbate the industry 
rivalry as other competitors in the market defend their share. Increased rivalry 
can lead to price wars or expensive marketing battles, which may cost more than 
any market share gains are actually worth. If retaliation is a danger, the company 
needs strategic capabilities that give a clear competitive advantage.108 The 
dangers of provoking fierce retaliation are greater in low-growth markers, as any 
gains in volume will be much more at the expense of other players.109 In low-
growth or declining markets, it can therefore be more effective to buy the 
competitors. By decreasing the number of independent players, buying the 
competitors can actually reduce the rivalry. 110 
Product development - Product development is when the company delivers new 
products to existing markets.111 There are three different ways of doing a product 
development: product extension, product replacement or product innovation. 
Product extension is when the company extends the existing product lines to give 
current customers greater choices. New features are added to enhance the value 
of the products.112 Product replacement is when old models or brands are 
replaced with new ones. The final option to a product development strategy is 
innovation; to replace an old product with a fundamentally different one. The 
new product is often based on a new technology.113  
Generally, there are two common approaches for innovation: technology push or 
market pull. In technology push the scientists create new knowledge, which form 
                                                             
105
 Johnson, G., Scholes, K. & Whittington, R., 2008, p. 258 
106 Jobber, D., 2007, p. 405 
107 Johnson, G., Scholes, K. & Whittington, R., 2008, p. 260 
108
 Johnson, G., Scholes, K. & Whittington, R., 2008, pp. 258-259 
109 Johnson, G., Scholes, K. & Whittington, R., 2008, p. 258 
110 Johnson, G., Scholes, K. & Whittington, R., 2008, pp. 259-260 
111 Johnson, G., Scholes, K. & Whittington, R., 2008, p. 261 
112 Jobber, D., 2007, p. 406 
113 Jobber, D., 2007, p. 407 
23 
 
the basis for new products. The new products are then “pushed” to the 
customers.114 Therefore, it does not matter if a certain demand already exists or 
not.115 Market pull is instead when the customers is responsible for the 
innovation.116 The source for the innovation is an inadequate satisfaction of 
customer needs, which results in new demands for problem-solving.117 
Market development - Market development is where companies deliver existing 
products to new markets, i.e. new users or new geographies.  The major challenge 
is to coordinate between different segments which might all have different 
needs.118 The risk of product development is that it can lead to saturation of 
existing market segments.  
Diversification - Diversification is a strategy where the company launches a new 
product on a new market.119 If a company has underutilized resources or 
competences it can use these for diversification into new activity.120 Another 
common justification for the diversification strategy is to spreading the risk. The 
diversification can be related or unrelated. Related diversification is a product 
development beyond current products and markets, but within the capabilities of 
the company. An unrelated diversification is just the opposite, a development of 
products beyond the current capabilities.121 
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4. Empirics: Cancer and Methods for Cancer Detection 
 
Chapter four contains information about cancer, breast cancer, as well as current 
techniques to detect breast cancer.  
 
4.1 Cancer 
“Cancer represents a tremendous burden on patients, families, and societies. It is 
one of the leading causes of death in the world and is still increasing, particularly 
in developing countries. Almost seven million people die each year of cancer, and 
many of these deaths can be avoided if appropriate measures are put in place to 
prevent, early detect, cure and care….”122 
  - Dr LEE Jong-Wook, Director-General, WHO 
 
Cancer is not a single disease but a group of diseases of which there are over a 
hundred types.123 The disease is characterized by uncontrolled growth and spread 
of abnormal cells. It can be classified into two types: hematological (malignancies 
of the blood) or solid tumors.124 If the tumors are spreading, they are referred to 
as malignant tumors, i.e. cancer is present. There are also tumors that are not 
cancerous, known as benign. Benign tumors are growing slowly, they do not 
spread and they are rarely life-threatening.125 
 
More than 11 million people are diagnosed with cancer every year and it is 
estimated that there will be 16 million new cases per year by the year 2020.126 
Cancer is the second leading cause of death in economically developed countries, 
following heart diseases, and the disease are becoming more common also for the 
less developed countries. Already half of all cancer cases occur in developing 
countries.127  
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Figure 4.1 shows the estimated number of new cancer cases in the year of 2007 
sorted by geographical area.  
   
 
Figure 4.1 – Estimated number of New Cancer Cases by World Area, 2007.128 
The number of deaths caused by cancer is constantly increasing, with an expected 
rise by 45% from 2007 to 2030, from 7.9 million to 11.5 million deaths. This is due 
largely to an increase in both population and life expectancy.129  
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Cancer is about as common among men as among women, but men and women 
are affected by various forms of cancer.130 As seen in Figure 4.2, the most 
commonly diagnosed cancers for men are lung- & bronchus, prostate and 
stomach cancer, and for women it´s breast, cervix uteri and colon- & rectum 
cancer.131 
 
 
Figure 4.2 – Estimated new cancer cases and deaths worldwide year 2007.132 
 
There are many causes of cancer and often a variety of factors interact in a 
complicated way for cancer to occur. There are different risk factors that 
contribute to causing cancer, both external and internal factors. Examples of 
external factors are tobacco, chemicals, radiation and infectious organisms. Some 
examples of internal factors are inherited mutations, different hormones, immune 
conditions and mutations.133 Depending on type and stage of the disease, cancer 
can be treated by surgery, radiation therapy, hormone therapy, biological therapy 
or chemotherapy.134 
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4.1.1 Breast Cancer 
Breast cancer represents a major public health problem, with over 1 million new 
cases each year.135 Table 4.1 shows the number of new breast cancer cases and 
the prevalence (the total number of cases) the year 2006 in some of the most 
affected countries. 
 
Country New Incidences 2006 Prevalence 2006 
France 42907 199746 
Germany 55366 236736 
Italy 37053 No information found 
Spain 16047 73242 
UK 41664 164963 
Japan 33215 152593 
USA 223543 1049964 
Sweden136 7096 No information found 
Table 4.1 – New incidences and prevalence of breast cancer across the seven major markets, 
2006.137 
Death rates from breast cancer have been steadily decreasing due to a 
combination of early detection and improved treatment. Nevertheless, 40-60% of 
all patients diagnosed with breast cancer will die from the disease.138  At stage 0, 
also referred to as Ductal Carcinoma In Situ (DCIS), which is defined by the 
absence of invasion of surrounding tissues, the five-year survival rate is 100%, but 
for women with stage IV (cancer has spread beyond the breast) its only 16%.139 
Considering these facts, it is apparent that more effective methods for early 
detection of this malignancy are urgently needed. 
 
A female breast consists of a number of milk glands where the breast milk is 
formed. Each gland has a milk duct, a passage that leading the milk to the nipple. 
The rest of the breast is made up by fat and connective tissue. In most cases 
breast cancer begins in the ducts, but it can also originate from milk glands or 
from connective tissue cells.140 
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The cause of breast cancer is unknown, but researchers have found a number of 
potential risk factors for breast cancer. These can be divided into seven 
categories: age, family history of breast cancer, hormonal factors, proliferative 
breast disease, radiation of the breast region, personal history of malignancy and 
lifestyle factors. 
 
Age - Increasing age is the single most important risk factor for developing breast 
cancer.141 The age-specific probabilities of developing breast cancer are shown in 
Table 4.2. 
 
Age-specific Probabilities of Developing Breast Cancer 
Current age Probability of developing breast 
cancer in the next 10 years [%] 
20 0.05 
30 0.44 
40 1.46 
50 2.73 
60 3.82 
70 4.14 
Table 4.2 – Age-specific probabilities of developing breast cancer. (The information is based on 
cases diagnoses 2000-2002.)
142
 
Though the risk for having breast cancer rises with age, it is important to know 
that the breast cancer tends to be more aggressive when it occurs in younger 
women.143 
Family history - 5–10% of all breast cancer cases result from inherited mutations 
in breast cancer susceptibility genes, such as BRCA1 and BRCA2.144 Women with a 
family history of breast cancer therefore have an increased risk of developing 
breast cancer themselves. If a first-degree relative (i.e., mother, sister or 
daughter) have a history of breast cancer the relative risk is 1.8 times higher than 
it would be otherwise.145 
 
                                                             
141 Hunt, K., Robb, G., Strom, E., & Ueno, N. (eds.), 2008, p. 31 
142 Hunt, K., Robb, G., Strom, E., & Ueno, N. (eds.), 2008, p. 32 
143 Zebrowski, M., 2007, p. 33 
144 American Cancer Society, 2009, p. 9 
145 Hunt, K., Robb, G., Strom, E., & Ueno, N. (eds.), 2008, p. 32 
30 
 
Hormonal factors - Early menarche (before 12 years of age), late menopause 
(after 55 years of age) and late age at first full-term pregnancy (35 years or older) 
increase a woman’s risk of breast cancer by affecting the reproductive 
hormones.146 Exogenous hormones, for example birth control pills, have also been 
linked to increase the breast cancer risk. Findings from an analysis done by the 
Collaborative Group (1996) showed that women who use birth control pills had a 
slightly increased risk of developing breast cancer.147 In contrast, a more recent 
finding from the Women’s Contraceptive and Reproductive Experiences trial 
(2002) indicated that users of birth control pills did not have an increased risk of 
developing breast cancer.148 
 
Proliferative Breast Disease - Some women with a history of abnormal breast 
tissue have an increased risk for developing breast cancer. The degree of increase 
in risk depends on the specific epithelial abnormality.149 
 
Radiation of the Breast Region at an Early Age - Radiation of the breast during 
early age (before 30 years) increases the risk of breast cancer. The greatest risk is 
seen in individuals exposed to radiation before age 15; some studies suggest as 
great as a 35% increased risk of breast cancer in such individuals by the age 40.150 
 
Personal History of Malignancy - A personal history of breast cancer increases the 
risk of a subsequent breast cancer. Personal history of other malignancy, such as 
endometrial, ovarian or colon cancer, may also increase the risk of developing 
breast cancer.151 
 
Lifestyle Factors – Several lifestyle factors play a significant role in determine an 
individual´s risk of breast cancer, for example diets with high fat and red meat 
content. Also high alcoholic consumption leads to increased risk for developing 
breast cancer.152 A recent study published in the Journal of Cancer Epidemiology 
(2009) has proved that being overweight also leading to an increased risk for 
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breast cancer. The risk depends on how late in life the weight gain occurs, for 
example a women who gains more than 10 kilo after age 30 or more than 5.5 kilos 
after age 40, has almost twice the risk to develop breast cancer as a women 
whose weight is stable. The research teams also found that smoking a pack of 
cigarettes a day for nine years increases breast cancer risks by 59%.153 
 
 
The earliest sign of breast cancer is often an abnormality detected on a 
mammogram screening or a lump felt by the woman or health care professional. 
Other, less common, symptoms are persistent changes to the breast such as 
thickening, swelling, distortion, tenderness, skin irritation and redness, or nipple 
abnormalities such as ulceration, retraction and spontaneous discharge.154  
 
How the cancer should be treated depends on the stage and biological 
characteristics of the cancer, as well as the patient’s own preferences.155 Most 
patients will have some type of surgery, often combined with other treatments 
such as radiation therapy, chemotherapy, hormone therapy or biologic therapy. 
The primary goal of breast cancer surgery is to remove the cancer from the breast 
and to assess the stage of disease. There is two way of conducting a surgery, 
either by mastectomy or lumpectomy. In a mastectomy the entire breast is 
removed and in a lumpectomy, only the tumor plus a rim of normal tissue is 
removed. Lumpectomy is almost always followed by about five to seven weeks of 
radiation therapy.156 Radiation is used to destroy cancer cells remaining in the 
breast, chest wall or underarm area after surgery. It could also be used to reduce 
the size of a tumor before surgery.157 A woman who chooses lumpectomy and 
radiation will have the same expected long-term survival as if she had chosen 
mastectomy.158  
 
Since the cause of the disease remains unknown, early detection and diagnosis is 
the key for breast cancer control. It can increase the probability of successful 
treatment, save lives and reduce costs. 
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4.2 Current Techniques for Breast Cancer Detection 
Segmentation of the different techniques has been done to better organize the 
empirical data. The techniques have been divided into two segments depending 
on the users’ different needs. The segments are screening tests and diagnostic 
tests.  
Segment Tests 
Screening tests Mammography 
Magnetic Resonance Imaging (MRI) 
Sonography 
Breast Physical Examination (BPE) 
Breast Self-Examination (BSE) 
Ductal Lavage (DL) 
Thermography 
Diagnostic tests Biopsy 
Magnetic Resonance Imaging (MRI) 
Tumor Marker Test 
Mammography 
Sonography 
Nuclear Medicine Breast Imaging  
Computerized Tomography (CT) 
Positron Emission Tomography (PET) 
Table 4.3 – The segmentation of the different technologies for breast cancer detection. 
Screening tests - Because early breast cancer is asymptomatic, the only way to 
detect it is through screening. Screening tests are given routinely to people who 
appear to be healthy and are not suspected of having breast cancer. The goal of 
this type of tests is to identify all individuals who might have breast cancer. 
One subgroup of the screening patients is women who have a higher risk for 
developing breast cancer. These are referred to as risk group screening. Women 
at high risk include those who:159 
 
• Have a known BRCA1 or BRCA2 gene mutation. 
 
• Have a first-degree relative with a BRCA1 or BRCA2 gene mutation. 
 
• Have a lifetime risk of breast cancer of 20%-25% or greater, according to risk 
assessment tools that are based mainly on family history. 
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• Had radiation therapy to the chest when they were between the ages of 10 and 
30 years. 
 
• Have Li-Fraumeni syndrome, Cowden syndrome or Bannayan-Riley-Ruvalcaba 
syndrome, or have a first-degree relative with one of these syndromes.  
 
• Have a personal history of breast cancer. 
 
The screening tests are: Mammography, Magnetic Resonance Imaging (MRI), 
Sonography, Breast Physical Examination (BPE), Breast Self-Examination (BSE), 
Ductal Lavage (DL) and Thermography. 
 
Diagnostic tests - Diagnostic tests are given to people who are suspected of 
having breast cancer, either because of symptoms they may be experiencing or 
after abnormal findings in screening test. These tests are used to determine 
whether or not breast cancer is present and, if so, whether or not it has traveled 
outside the breast. Diagnostic tests also are used to gather more information 
about the cancer, for example the location and the size of the tumor, to guide 
decisions about treatment. 
Once breast cancer is diagnosed, tests are used during and after treatment to 
monitor how well therapies are working. These tests is often referred to as 
monitoring tests, but because both the tests and the need they satisfy is the same 
as the diagnostic tests, will these tests also be referred to as diagnostic tests. 
The diagnostic tests are: Biopsy, Magnetic Resonance Imaging (MRI), Tumor 
Marker Test, Mammography, Sonography, Nuclear Medicine Breast Imaging, 
Computerized Tomography (CT) and Positron Emission Tomography (PET). 
 
Two important concepts most be defined before the different techniques are 
presented: sensitivity and specificity. The sensitivity represents the proportion of 
truly diseased persons in a population who are identified as being diseased by the 
test. It is a measure of the probability of correctly diagnosing a condition.160 
Specificity of a test is defined as the percentage of persons without the disease of 
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interest who have negative test results. It is a measure of the probability of 
correctly identifying a non-diseased person.161 A more detailed explanation of the 
two concepts can be found in Appendix B. 
A complementary analysis of future techniques, which are under various stages of 
research and development, has also been conducted and is presented in Appendix 
C.  
4.2.1 Screening Tests 
Mammography 
Mammography is an x-ray method for evaluation of breast tissue. The first 
mammography unit was introduced in 1965, and ever since then, mammography 
screening trials and programs for detecting breast cancer have been organized all 
around the world.162 Today mammography is the most widely used imaging 
modality for early detection of breast cancer.163 
 
In mammography, the breasts are compressed between two plates while a special 
camera takes pictures of the breasts.164, 165 Tumors are detected on the basis of 
differences in x-ray attenuation, distortions in tissue architecture or appearance 
of certain patterns of micro calcifications (tiny specks of calcium in the breast).166  
 
Mammography can be done in standard or in digital form. In standard 
mammography, images are recorded on film using an x-ray cassette. The film is 
then viewed by the radiologist using a light box. In digital mammography, the 
breast image is captured using a special electronic x-ray detector, which converts 
the image into a digital picture for review on a computer monitor. Digital 
mammography uses the same mammographic system as conventional 
mammography, but the system is equipped with a digital receptor instead of a 
film cassette.167 The digital mammography has an advantage that the systems 
offer opportunities for post-processing and reconfiguring of the original data.168  
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Figure 4.3 – The mammography equipment and a mammogram of a breast. The arrow shows a 
high-density, irregular mass that indicate cancer.169, 170 
Leading experts in the U.S. such as the American Cancer Society (ACS), the 
American College of Radiology (ACR) and the National Cancer Institute (NCI) 
recommend annual mammograms for women over 40.171 The Swedish authority 
Socialstyrelsen, recommend mammograms for women 40-74 year, with 18-
months intervals for women 40-54 year and 2-years intervals for women age 55-
74 year.172 The specificity of mammography is 95.7% and the sensitivity is 79%.173 
The cost of a mammogram is $150 to $200 per scan.174  
In mammography x-rays are used, which are photons with higher energy levels 
than visible light. This radiation, which is powerful enough to knock electrons 
from atoms, is known as ionizing radiation. Because the body absorbs some of the 
ionizing radiation used in mammography, the radiation can cause damage at the 
molecular level and produce adverse health effects.175 The radiation dose received 
during a screening mammogram is about the same amount of radiation a person 
gets from the natural surroundings in an average 3-month period (0.7 mSv).176   
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Several studies have been done to evaluate mammography as a screening test, 
i.e. Shapiro et al. (1988), Mettlin & Smart (1994), Tabar et al. (1995), Andersson & 
Janzon (1997), Hendrick et al. (1997), Smart et al. (1997) and Feig et al. (1998). 
These studies showed that screening mammography in women aged 40 years and 
older reduces cancer deaths by 29 to 45%.177 In contrast, a more recent study 
done by Gøtzsche & Olsen (2000), found no reduction in mortality with 
mammography, so the authors concluded that screening for breast cancer with 
mammography is unjustified.178  
 
It is difficult to interpret mammography for young women because their breasts 
tend to be dense and full of milk glands.179 The sensitivity of standard 
mammography in dense breast is therefore only 30 to 48%.180 Digital 
mammography is somewhat more sensitive in women with dense breasts, but 
outcome studies are lacking.181 In addition, some literature has evaluated the 
relationship between breast density and the risk of developing cancer. Two 
specific studies of 237 and 622 women each concluded that the risk of breast 
cancer is increased 2.2- to 5-fold in patients with dense breasts compared with 
those with fatty breasts.182, 183  Another area where mammography is of limited 
value is in the examination of breasts containing implants.184  
Mammography can also be uncomfortable or even painful for some women, 
because the breast is compressed to flatten and reduce the thickness of the 
breast.185 This pain makes some women avoid this potentially life-saving screening 
procedure.186  
According to the American Cancer Society, about 10% of women who have a 
mammogram will require more screening tests. 187 
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Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging is based on the discovery of Nuclear Magnetic 
Resonance (NMR). NMR is a physical phenomenon that was discovered by two 
American research teams, Bloch et al. and Pound et al., in 1946. They found, 
independently of each other, that when certain nuclei were placed in a magnetic 
field they absorbed energy in the radiofrequency range and re-emitted this 
energy during the transition to their original orientation. The technique was 
referred to as Nuclear Magnetic Resonance.188, 189 However, as the word nuclear 
was associated in the public mind with nuclear warfare, the adjective nuclear was 
dropped when the method was introduced to clinical practice in the early 
1980s.190  
MRI uses a static magnetic field (commonly between 0.5-3 Tesla) to align the 
nuclear magnetization of hydrogen atoms in water. Radio frequency pulses are 
used to systematically alter the alignment of this magnetization, causing the 
hydrogen nuclei to absorb and then re-emit the energy in a way that reveals 
information about the physical and chemical properties of the tissue´s 
environment in the body. For better contrast, patients get contrast agents 
injected. These agents enhance the tissue contrast by increasing the brightness in 
various parts of the body where the agent resides. The most common contrast 
media used today is made up of individual atoms of gadolinium, which are held 
tightly by a non-toxic small molecule, to prevent toxic effects.191, 192 
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Figure 4.4 – The MRI equipment and an MRI picture, there the arrow points to a high-density, 
irregular mass that indicate cancer.193, 194 
American Cancer Society is not recommending MRI for screening women at 
average risk of breast cancer, but they recommend annual screening with MRI for 
women with high risk, so called risk group screening.195 The specificity of MRI 
(conducted with current contrast agents) is 72.4% and the sensitivity is 92.5%.196 
The cost of an MRI examination is $1,000 to $1,500 per scan.197 
MRI uses radio-frequency waves, which are photons with energy levels lower than 
visible light. This low-energy radiation is non-ionizing and is considered much 
safer than ionizing radiation.198 MRI has no limitations in terms of detecting 
cancer in dense breasts or in breasts with implants.199 
 
One in ten women diagnosed with cancer in one breast will develop the disease in 
the opposite breast, the contralateral breast.200 Liberman et al. (2003) performed 
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a study that included 223 women with known breast cancer who underwent MRI 
of a mammographically normal contralateral breast. Cancer was detected by MRI 
in 12 women (5%).201 Based on the results of this and other studies, the American 
Cancer Society now recommends that women diagnosed with cancer in one 
breast have an MRI scan of the contralateral breast.202 
 
The presence of micro calcifications is a strong indication that Ductal Carcinoma In 
Situ (DCIS) is present. Breast MRI can´t detect micro calcifications because the 
calcium don´t give any signals.203 However, a study done by Kuhl et al. showed 
that MRI was better than mammography at finding DCIS. About 90% percent of 
DCIS was found by MRI, while only 56% was found by a mammogram204 On the 
other hand, small foci of DCIS (less than 3 mm in diameter) was often missed on 
MRI and the extent of DCIS is overestimated by MRI in 50% of cases.205, 206  
 
 
Sonography 
Sonography of the breast, also called breast ultrasound, is a sound based imaging 
modality and was first described in 1952 by Wild & Reid.207 The scanners consist 
of a console containing a computer, a display screen and a transducer, a small 
hand-held device that resembles a microphone attached to the scanner by a cord. 
The transducer sends out high frequency sound waves into the body and then 
listens for the returning echoes. The image is created based on the amplitude 
(strength), frequency and the time it takes for the sound to return from the 
patient to the transducer.208 
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Figure 4.5 – The Sonography equipment and a Sonography image that show a cluster of small 
calcifications that may indicate that cancer is present.209,210 
Sonography is not recommended to any major group as a screening tool; it is only 
used to complement other screening tests.211 The sensitivity is 86.1% and the 
specificity 66.4%.212 The cost of a sonography examination is $150.213 
Sonography involves no radiation, only harmless sound waves. The method has no 
limitation in dense breasts, but it is technically difficult to interpret the method in 
women with large breasts.214, 215  
According to a study published in European Radiology, the detection rate doubled 
when Sonography and mammography were combined compared to 
mammography alone. The authors believe the technology's effectiveness could 
justify adding it to the screening routine for women with dense breasts or women 
at high risk for breast cancer. One important thing to take into account is that 
women with compressed breast thickness at mammography of greater than 7 cm 
were specifically not recruited because of ultrasound's limited effectiveness at 
these depths, according to the study team.216 
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Breast Physical Examination 
Breast Physical Examination (BPE), also referred to as Clinical Breast Examination 
(CBE), is a manual examination of the breasts done by a doctor or other health 
care professional. The doctor seeks to detect breast abnormalities to find palpable 
breast cancers at an early stage of progression.217  
The American Cancer Society (ACS) recommends that women in their 20s and 30s 
have a Breast Physical Examination every three years and after the age of 40 this 
exam should be done every year.218 The method is not used as the only screening 
method but rather as a complement to mammography. The specificity of Breast 
Physical Examination is 94% and the sensitivity is 54%.219 Studies have shown that 
the accuracy of BPE is highly dependent on time taken to do the examination.220 
Exact costs are not available but the method is likely to be inexpensive since no 
equipment is required.  
About 20% of the breast tumors that are not seen on a mammogram are detected 
by a BPE.221 A controversial Canadian study found that BPE is as effective as 
mammography in reducing mortality from breast cancer in women aged over 50. 
The scientists found that mammography detected breast cancers earlier than with 
BPE, but unexpectedly, earlier detection did not translate into a survival 
advantage.222 The reliable of the study can be discussed; many other studies have 
shown that earlier detection of breast cancer is in fact leading to fewer deaths.223 
A study published in the Journal of the National Cancer Institute (2009), shows 
that breast cancer rates and sensitivity was higher, but so were also the false-
positive rates, among women who did a BPE in addition to Mammography. For a 
theoretical population of 10,000 women between ages of 50 and 69 years, the 
addition of BPE would lead to the detection of breast cancer in only four women 
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whose cancers would be missed by Mammography. However, adding BPE would 
also lead to false-positive results for an additional 219 women.224 
 
Breast Self-Examination 
In Breast Self-Examination (BSE) the women receive instructions by a health care 
professional so she can examine her own breast and hopefully detect any 
changes.225 The American Cancer Society recommendations regarding BSE are 
that women in their 20s should be told about the benefits and limitations of the 
method. It is then up to the woman herself if she wants to implement them or 
not.226  
 
The contribution of the Breast Self-Examination to early detection is difficult to 
determine. There is no available data on the method sensitivity or specificity, but 
the values can be assumed to be low. The methods cost is not available, but the 
method is inexpensive since no equipment is required and the only cost is 
associated with the woman's instructions. 
In the recent years there have been a shift from formal teaching of a technique 
for Breast Self-Examination to only reinforcing the importance of a woman’s being 
familiar with her breasts.227 This change was implemented after findings from a 
large trial of Breast Self-Examinations conducted in Shanghai, China, showing that 
the practice of regular BSE by trained women does not reduce breast cancer-
specific or all-cause mortality at all. In fact, there is as many cancers detected 
incidentally as were found by women trained to do routine Breast Self-
Examinations. 228  
 
Another study, done by the Cochrane group, indicates that BSE increases the 
number of biopsies that is performed. The Cochrane group viewed this as 
evidence of harm and recommended that women should not perform Breast Self-
Examination.229  
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Ductal Lavage 
Ductal Lavage (DL) is a method where malignant cells can be found in fluid 
expressed from the breasts of women with breast cancer. The method was first 
suggested as a screening test in the 1950s by Dr. Papanicolaou, but the technique 
was developed first 2001 by Susan Love and her team.230 
In Ductal Lavage a micro-catheter is inserted into the nipple and a small amount 
of salt water is released into the duct to rinse out cells. The fluid, then referred to 
as Nipple Aspirate Fluid (NAF), is pulled back out of the nipple and sent to the 
laboratory for analyze.231  
 
Figure 4.6 – The principle of Ductal Lavage.232 
The American Cancer Society don´t recommend Ductal Lavage as an independent 
screening or even as a complement to mammography.233 The specificity of Ductal 
Lavage is 96% and the sensitivity is 43%.234  The cost is approximately $250 to 
$300 per procedure. 235 
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By washing out a milk duct, the general area of the breast that has abnormal cells 
can be found, but not the exact location. So, Ductal Lavage must always be 
followed up with other tests.236 
 
Ductal Lavage is meant to be used as a screening test for high risk groups, for 
example carriers of BRCA1/2 mutations. A recent study was conducted to 
evaluate the role of Ductal Lavage in breast cancer screening among these high-
risk women. The results were that 74% of the potential candidates did not yield 
any NAF and 37% could not even have the duct cannulated. The women also 
found the technique painful and were reluctant to undergo multiple Ductal 
Lavage examinations over time. The researchers show this as evidence that Ductal 
Lavage is not likely to play any central role in breast cancer screening among high-
risk women.237 
 
 
Thermography 
Thermography is a graphic display of the infrared radiation from the breast and 
has been used for breast cancer detection, as an adjunct to mammography, since 
1982. Its inception dates to Lawson’s observations in 1956 that breast cancer may 
be warmer than the surrounding tissue.238 The method uses a special heat-
sensitive imaging device to measure the temperature of the skin on the breast’s 
surface. Because cancer cells are growing and multiplying very fast, blood flow 
and the metabolism are higher in a cancer tumor and therefore the skin 
temperature goes up.239 
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Figure 4.7 – The Thermography equipment and an infrared picture that shows a significant 
amount of heat in the right breast that indicates breast cancer.240, 241 
The American Cancer Society does not recommend thermography as a 
replacement for mammography, but only as a supplement to help identify cancers 
that are close to the skin.242 According to literature the sensitivity and the 
specificity are 85% and 70%, respectively.243 The cost for a breast thermography 
examination is generally around $200, depending on radiologist reading fees.244 
In April 2009 the Oregon Department of Justice shut down a health clinic in 
Medford because they had misrepresented the efficacy of thermography as a 
breast cancer detection tool. Ever since that there is an ongoing debate, with the 
major question: is thermography a legitimate adjunctive breast imaging technique 
or not? According to Dr. Leonard Berlin, chair of radiology at Rush North Shore 
Medical Center in Skokie, the problem is that the technique never has been 
proved clinically (or at least in no trustworthy study).245 
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4.2.2 Diagnostic Tests 
Biopsy 
A biopsy is a small operation done to remove tissue from an area of concern in 
the body, either by a very thin needle, fine-needle aspiration (FNA) or with a 
larger needle, so called coarse-needle biopsy (CNB).246 The tissue sample is then 
examined by a pathologist to establish whether the lump is malignant or 
benign.247 Biopsy is the most common method to classify the tumor, but it is not 
an imaging test that can determine location or size of the tumor. 
 
Figure 4.8 – The procedure of a coarse-needle biopsy.248 
Biopsy has 100% specificity and the sensitivity is 82% for CNB and 75% for FNA.249 
The cost of CNB and FNA is approximately $400 and $250, respectively.250 
In the United States, 20% of women who have biopsies turn out to have cancer. In 
Sweden where only the most suspicious cases are biopsied, 80% of the biopsies 
turn out to be cancerous.251  
A major study performed by Bruening et al. (2006) evaluated biopsy compared to 
non-invasive diagnostic tests. The researchers concluded that none of the non-
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invasive diagnostic tests (MRI, Sonography, PET and Nuclear Medicine Breast 
Imaging) were accurate enough to replace biopsy.252 
 
Magnetic Resonance Imaging 
MRI can classify if tumors are malignant or benign. The visualization is based on 
rapid enhancement after the administration of the contrast agent as well as 
morphologic characteristics. Malignant tumors, including DCIS, tubular carcinoma 
and invasive lobular carcinoma, have slower, less intense enhancement patterns 
than benign tumors.253 There is also computer-aided kinetic information that 
further enhancing the methods ability to distinguish malignant from benign 
tumors.254 However, MRI is also associated with false positives. In one study of 48 
patients, MRI overestimated the extent of disease in 21%.255  
 
Studies have shown that MRI can demonstrate the extent of cancer in the breast 
more accurate than Mammography, Sonography and Positron Emission 
Tomography.256 
The MRI method can also be used to see if the cancer has traveled outside the 
breast, for example whether there are any cancer cells in the lymph nodes. 
Whether or not there are cancer cells in the lymph nodes is an important factor 
doctors consider when deciding if chemotherapy or radiation therapy should be 
given after surgery to lower the risk of the cancer coming back. Today, the nodes 
are examined during surgery.257  
 
Tumor Marker Tests 
In a Tumor Marker test the doctor takes a sample of blood, urine or body tissue 
and sends it to a laboratory to look for, so called, tumor markers. Tumor markers 
are substances, usually proteins, which are produced by cancer cells or by other 
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cells of the body in response to cancer. Tumor markers are also called serum 
markers or biomarkers.258 Examples of tumor markers are: CA 15.3, CA 549, CEA 
and MCA.  
The sensitivity of the method differs depending on the tumor marker that are 
sought, for example are the sensitivity for CEA 45%, for MCA 59%, for CA 15.3 71% 
and for CA 549 72%.259 There are no available data about the specificities of the 
methods. According to literature are the tests very expensive, but there are no 
available data of exact costs.260 
Oncologists use tumor marker tests to diagnose and monitor cancer. These tests 
can be used to determine whether or not cancer is present, i.e. if the tumor is 
malignant or benign and to help determine the stage of the cancer. Tumor marker 
tests are also used to measure the progress during treatment. If the tumor marker 
levels decrease, then the cancer is responding to the therapy, an increased level 
indicates that the cancer is resisting the treatment.  These tests are not imaging 
tests so they can’t determine size or location of the tumors.261 
 
Mammography 
Mammography has an established role in breast cancer diagnosis. It is used to 
define the extent of malignancy before surgery and to monitor the breast after 
surgery and radiation therapy.
262 Mammography is also used to guide biopsies.263 
Diagnostic mammograms are different from screening mammograms in that they 
focus on getting more information about a specific area of concern, usually due to 
a suspicious screening mammogram. In diagnostic mammography more pictures 
are taken than in a screening mammogram.264 
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Sonography 
Sonography is one of the most frequently used diagnosis tools to classify 
abnormalities of the breast. With sonography it is possible to determine the 
location, size, shape and to see whether a breast lump is fluid-filled (a cyst) or if it 
is a solid lump. 265 A lump that has no fluid or that has fluid with floating particles 
may need more tests.266 
One advantage of the method is that images can be obtained from almost any 
orientation.267 Because Sonography provides real-time images, it is also often 
used to guide biopsy procedures.268  
Sonography can´t show areas deep inside the breast or show micro 
calcifications.269 Sonography cannot always determine whether a solid lump is 
cancerous, nor can it detect DCIS, because the volume of the intraductal lesion is 
usually too small.270, 271  
 
Nuclear Medicine Breast Imaging 
The Nuclear Medicine Breast Imaging starts with an injection of a radioactive 
tracer. The local concentration of radioactive tracer is higher for cancer cells than 
for normal cells. Imaging can begin 5 to 15 minutes after the administration of 
radiotracer.272 The patient are then lying face down on a special table while the 
breast hangs down through an opening in the table. A special gamma camera is 
then used to take images of the breasts. The method involves the use of 
radiation.273  
 
The method is not only referred to Nuclear Medicine Breast Imaging, sometimes it 
is called Molecular Breast Imaging or Scintimammography. Currently, only the 
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Miraluma Tc-99m sestamibi compound, manufactured by DuPont 
Pharmaceuticals, is approved for breast imaging. Therefore, the Nuclear Medicine 
Breast Imaging test may also be referred to as a "Miraluma test”.274  
 
Figure 4.9 – The Nuclear Medicine Breast Imaging equipment and a picture 
taken with the technology.275 
Nuclear Medicine Breast Imaging has 84.8% specificity and 68.7% sensitivity.276 
The test takes approximately 45 minutes to one hour to perform and costs $200 
to $600 per exam.277 
Nuclear Medicine Breast Imaging is used to determine the size and the location of 
the tumor and to help physicians classifying the tumor, based on the 
accumulation of the radiotracer.278 Studies show that nuclear medicine breast 
imaging are 90% accurate in detecting abnormalities over one centimeter, but 
only 40% to 60% accurate in imaging small breast abnormalities (less than 1cm) 
and are unable to identify DCIS.279, 280  
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Nuclear Medicine Breast Imaging has no limitation regarding dense breasts or the 
presence of scar tissue or implants.281 
In an Italian study, mammography and Nuclear Medicine Breast Imaging were 
compared. While the overall accuracy of the two tests were similar, Nuclear 
Medicine Breast Imaging was better to see the breast cancer in younger 
women.282 
 
 
Computerized Tomography 
The first reports of computerized tomography (CT) for evaluating breast disease 
was described 1977 by Chang. A CT scan is an X-ray technique that gives 
information about the body’s internal organs in 2-dimensional slices. During a CT 
scan, the patient lies on a table that passes through a doughnut-shaped machine. 
A computer puts the x-rays together to create detailed pictures of the inside of 
the body. Before the test, a contrast agent is injected.283 
 
Figure 4.10 – A CT scan and a CT image of a breast. 284,285 
The sensitivity and the specificity are at mediocre level, 71.9% and 83.3%.286 The 
cost of a CT scan is between $500 and $700.287 
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The method is often used to assess whether or not the cancer has moved into the 
chest wall. This helps determine whether or not the cancer can be removed with 
mastectomy. The method is also used in order to examine other parts of the body 
where breast cancer can spread, such as the lymph nodes, lungs, liver, brain and 
spine. It also used to see whether or not the cancer is responding to the cancer 
treatment.288  
The CT provides three-dimensional images of the breast, compared with just two-
dimensional images for mammography, which eliminates image artifacts 
(suspicious areas that result from normal breast structures overlaying each other 
when the breast compresses).289  
The radiation dose received during a breast CT is about the same amount of 
radiation a person gets from the natural surroundings in an average 2-years 
period (7 mSv).290 This greatly exceeds the American College of Radiology 
recommendation of ≤ 3 mSv. Breasts CT can therefore actually lead to cancer, but 
the potential carcinogenic effects are unknown.291 
Because of the high cost of the examination and the high radiation dose is an 
inappropriate breast cancer screening tool and is only used in selected cases to 
show the extension of metastasis and to reveal skeletal destruction of the 
sternum and chest wall.292 
 
Positron Emission Tomography 
Positron Emission Tomography (PET) for breast was first described in 1988 by 
Mintun.293 The method can detect areas of cancer by obtaining images of the 
body’s cells as they work. Before a PET scan, a small amount of radioactive 
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material is injected into the bloodstream and because cancer cells tend to be 
more active than normal cells, they also absorb more of the radioactive material. 
A special camera then scans the body to pick up any highlighted areas on a 
computer screen. 294 
 
Figure 4.11 – The PET scan equipment and an image taken with PET. The yellow arrow indicates a 
primary tumor.295 
The sensitivity and specificity of PET in detecting malignant breast lesions is 93% 
and 75%, respectively.296 The cost of a PET examination is around $5,000 per 
scan.297 
 
PET can be used for detecting and staging breast cancer.298 PET scans can also 
help the doctor evaluate whether cancer still exists after radiation or 
chemotherapy and to see if the cancer has spread to the lymph nodes or other 
parts of the body.299  
PET has low sensitivity for small lesions and for slow-growing tumors such as DCIS 
and lobular carcinoma. 300 A PET scan gives radiation equivalent with six months of 
background radiation.301 
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4.2.3 Summary of the Techniques for Breast Cancer Detection 
In Table 4.4 and 4.5 the different methods for detection of breast cancer are 
being compared based on the sensitivity, specificity and cost. The symbol “-“ 
means that no information could be found. 
Screening tests 
 Sensitivity 
[%] 
Specificity 
[%] 
Cost [$] 
Mammography 79 95.7 150-200 
Magnetic 
Resonance 
Imaging (MRI) 
92.5 72.4 1,000-1,500 
Sonography 86.1 66.4 150 
Breast Physical 
Examination 
54 94 - 
Breast Self-
Examination 
- - - 
Ductal Lavage 43 96 250-300 
Thermography 85 70 200 
Table 4.4 – Summary of the screening tests. 
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Diagnostic tests 
 Sensitivity 
[%] 
Specificity 
[%] 
Cost [$] 
Biopsy FNA 75 
CNB 82 
100 FNA 250 
CNB 400 
Magnetic 
Resonance 
Imaging (MRI) 
92.5 72.4 1,000-1,500 
Tumor Marker 
Tests 
CEA 45 
MCA 59 
CA 15.3 71 
CA 549 72 
- - 
Mammography 79 95.7 150-200 
Sonography 86.1 66.4 150 
Nuclear Medicine 
Breast Imaging 
68.7 84.8 - 
Computerized 
Tomography 
 
71.9 83.3 500-700 
Positron Emission 
Tomography  
 
93 75 1,000-1,500 
Table 4.5 – Summary of the diagnostic tests. 
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5. Analysis of the MRI Technology 
 
Chapter five contains an analysis of the current MRI technology. The advantages 
and disadvantages, as well as possible areas for improvement, of the technology 
are discussed. 
 
5.1 MRI as a Screening Test 
Suitability criteria for a screening test include adequate sensitivity and specificity, 
low cost, easy administration, high safety and to impose minimal discomfort for 
the patients.  
The general method used today to screen for breast cancer is mammography, 
probably because of its low cost, high specificity and reasonable sensitivity. All 
other screening tests mentioned earlier are in fact not used on their own as a 
screening tool, rather as complements to mammography.  
The mammography is however not perfect. As previously mentioned, 
mammography involves ionizing radiation that can produce adverse health 
effects. MRI, on the other hand, uses radio-frequency waves, which are photons 
with energy levels lower than visible light. This low-energy radiation is non-
ionizing and is considered much safer than ionizing radiation.302 
Hundreds of women who participate in mammography screening programs are 
falsely reassured that they are free from breast cancer each year.303 MRI is 
significantly more sensitive in detecting cancers than mammography; 92.5% 
compared to 79%.304 The sooner cancer is diagnosed and treated, the better are 
the chances of full recovery, so if MRI was used as a screening tool there is no 
doubt that more lives could be saved. 
Mammography has also been the mainstay for the detection and evaluation of 
Ductal Carcinoma In Situ.305  However, MRI has gained increased popularity in the 
evaluation of DCIS after it had been shown that MRI is in fact better than 
mammography at finding DCIS. Since MRI appears to be better than 
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mammograms at detecting DCIS, more women who get screening MRIs will be 
diagnosed and treated for DCIS. This will reduce their risk of invasive breast 
cancer in the future. However, even though the sensitivity of MRI in detecting 
DCIS is shown to be higher than for mammography, the specificity was also 
lower.306  
 
Mammograms can be difficult to conduct in younger women because their breast 
tissue is dense. Therefore, Sonography is used to screen these younger women. 307  
MRI has, however, a higher sensitivity and specificity and will probably take over 
this roll in the future. MRI is also superior to mammography in detecting cancer in 
patients with breast implants and cancers in the contralateral breasts of women 
diagnosed with breast cancer.308 
 
Although magnetic resonance imaging shows promise as a screening tool, it is not 
currently recommended for general screening because of high false-positive rates 
(the specificity is only 72.4% compared to 95.7% for mammography) and high cost 
(1,000 to $1,500 per scan compared to $150 to $200 for a mammography). The 
cost is, however, something that can be discussed; it is not certain that the total 
cost will increase, as more patients receive their diagnosis earlier, which means 
less expensive treatments and higher survival rates. However, the low specificity 
means unnecessary recalls and biopsies, which also add to the total cost. 
 
We are likely to observe a paradigm shift in the manner in which breast cancer 
screening will be performed in the future. Breast cancer screening is currently 
performed in a standard manner for all women with mammography. However, 
this level of standardization is likely to be replaced by tailored screening programs 
with respect to the women’s individual risk of developing breast cancer. More and 
better tools are also being developed to find these women with increased risk for 
breast cancer, see Appendix C. Already elements of this change can be observed 
with the recommendation by American Cancer Society to use MRI for screening of 
these high-risk women. It is also this segment, screening high risk patients, which 
is the most important market segment for MRI in the field of breast cancer. 
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It is important to mention that the various screening tests do not always compete 
with each other, sometimes they actually complementing each other. Because 
mammography has a low sensitivity, about 10% of the women who had a 
mammogram will require more screening tests.309 It is therefore interesting to 
compare MRI, not only with mammography, but also with other screening 
methods. 
Both Breast Physical Examinations and Ductal Lavage are cheap, have a high 
specificity and don´t involve any radiation. The two methods have, however, 
really low sensitivities, so if tumors were not found with mammography they 
probably not will be found with the BPE or DL either.  
 
Thermography has reasonable sensitivity and specificity but the method can't 
detect cancers that are deeper in the breast or small cancers that don´t generate 
any heat. So the usefulness of this method is limited and the technique will 
probably not be commercially used to detect breast cancer. 
The MRI method´s major advantage compared to other screening tests is the high 
sensitivity, but the drawback is the relatively low specificity, which results in more 
recalls and biopsies.  
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5.2 MRI as a Diagnostic Test 
Diagnostic tests are used to classifying the tumors and to gather more information 
about the cancer, for example tumor size and exact localization, to guide 
decisions about treatment. 
 
For the purpose of classifying the tumor, i.e. to determine if the tumor is 
malignant or benign, biopsy is undoubtedly the most common method used 
today. However, only a low percentage of women undergoing biopsy actually 
have cancer, meaning unnecessary operations for the patients. Therefore, there is 
a demand for non-invasive diagnostic tests that are as accurate as biopsy. A major 
study performed by Bruening et al. (2006) evaluated the non-invasive diagnostic 
tests (MRI, Sonography, PET and Nuclear Medicine Breast Imaging) to see if there 
are any substitutes to biopsy. Their result was that none of the diagnostic tests, 
not even MRI, were accurate enough to replace biopsy.310  
Various imaging techniques (MRI, mammography, Nuclear Medicine Breast 
Imaging, CT, Sonography and PET) are used to determine the size and localization 
of the tumors. The most common methods are probably mammography and 
sonography. However, the high soft tissue contrast and three-dimensional format 
of MRI allows anatomic structures of the breast to be viewed in great detail. MRI 
can therefore demonstrate the extent of cancer in the breast more accurate than 
all other imaging tests (inclusive mammography and sonography).311  
The MRI method can also be used to see if the cancer has traveled outside the 
breast and to see if there are any cancer cells in the lymph nodes. Today, the 
nodes are examined during surgery, but as the study shows, MRI could be a better 
alternative.312  
Once breast cancer is diagnosed, many tests are used during and after treatment 
to monitor how well therapies are working. Monitoring tests also may be used to 
check for any signs of recurrence. Today, most follow-ups are made with 
mammography, despite that numerous studies have shown that MRI is superior to 
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mammography (and Sonography) for estimating tumor size. Tumor size is one of 
the most important factors when monitoring the progress of the therapy.313 
Why the MRI technique isn’t used to a higher extent for diagnostic purposes 
(determine size and localization of tumors) probably depends on a combination of 
a lack of availability, limited expertise of radiologists and the risk of 
overestimating the extent of disease. 
 
5.3 Summary of MRI´s Strength and Weaknesses 
To understand the characteristics of the MRI technology in a clear way, the most 
important strengths and weaknesses of the method is summarized in the text 
below. 
 
The strength of the MRI technology is the high sensitivity (92.5%). MRI also uses 
radio-frequency waves, which is non-ionizing energy and considered safe. MRI has 
no limitations in terms of detecting cancer in dense breasts or in breasts with 
implants. 
 
The major weakness of the MRI technology is the low specificity (72.4 %), 
meaning that many patients will be misdiagnosed. The cost is also relatively high, 
$1,000 to $1,500 per scan.  
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6. Empirics and Analysis of SPAGO´s Contrast Agent 
 
Chapter six contains a description of SPAGO´s contrast agent and a brief overview 
of the market of MRI and the existing contrast agents. The chapter also includes a 
SWOT analysis of SPAGO´s product. 
6.1 Empirics: Product Description 
SPAGO´s contrast agent is based on the so-called SPAGO-Platform: Safe 
Paramagnetic Gadolinium Oxide nanoparticles. The nanoparticles consist of 
gadolinium ions (Gd3+), which is a metal ion with special magnetic properties that 
allows it to enhance the tissue contrast in MRI. There are 1000-2000 gadolinium 
ions in every particle (conventional contrast agents have only one) and the ions 
have a higher individual efficacy than in conventional contrast agents. The size of 
a particle is approximately 10 nm in diameter and therefore small enough for 
being entirely excreted through the kidneys after administration.314 
 
Figure 6.1 – A particle of SPAGO´s contrast agent.315 
The gadolinium core (1) is encapsulated by a silicate network (2) and the surface is 
coated with a bioinert and durable polyether shell (3), see Figure 6.1. The shell 
encapsulates and protects the gadolinium ions from degradation. 
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 In the future, the idea is that the shell also will serve as attachment points for 
targeting molecules, which are molecules targeting a unique chemical structure of 
the diseased cell. This kind of imaging is called molecular imaging and is not 
possible today in MRI due to far too weak signal enhancement of the conventional 
MRI contrast agents. The contrast of the particles in SPAGO´s contrast agent is 
however higher, enough to enable molecular imaging in MRI, hence improving 
selective localization of diseased cells.316  
 
Figure 6.2 – A SPAGO particle with a fixed target molecule.317 
SPAGO´s contrast agent can selectively penetrate into tumor tissue, thus 
achieving what is called passive tumor targeting. Tumors have lots of small blood 
vessels around them. The walls in these blood vessels are composed of 
endothelial cells, which are usually damaged. Instead of being tightly packed 
blocks (as for healthy blood vessels) they are more irregular in structure, creating 
holes in the blood vessel walls. Since SPAGO's product consists of thousands of 
ions the particles are so large that they do not penetrate healthy vessels (or in to 
inflammatory tissue), which the commercial contrast agents do. However, the 
contrast agent can get through the holes formed in the damaged blood vessels. 
SPAGO´s contrast agent will therefore only distribute in approximately 5 liters, 
while the contrast agents that is available on the market today is spreading evenly 
all over the body and has a distribution volume of 50 liters.318  
                                                             
316 Axelsson, O., personal communication, September 8, 2009 
317 Axelsson, O. (oskar.axelsson@spagoimaging.se), 12 August, 2009 [e-mail] 
318 Axelsson, O., personal communication, October 14, 2009 
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Figure 6.3 – Passive tumor targeting.319 
 
The contrast agent is injected intravenously and the MRI study is performed after 
one to two hours.320  
 
One important thing regarding gadolinium-based contrast agent is that the U.S. 
Food and Drug Administration (FDA) and other medical agencies recently have 
recognized some safety issues in connection with the use of conventional non-
encapsulated gadolinium-based contrast agents (GBCA). 321 
Nephrogenic Systemic Fibrosis (NSF), also known as Nephrogenic Fibrosing 
Dermopathy (NFD), is a sometimes fatal condition that can cause fibrosis of the 
bone, kidneys, lungs, muscle and other structures. Although the cause of the 
disease is not fully understood, it has been closely connected to patients with 
kidney problems who receive large doses of GBCA.322 A survey shows that 
approximately 400 cases of NSF have been reported worldwide and as many as 
90% of them had previously received gadolinium-based contrast agents.323 U.S. 
Food and Drug Administration (FDA) are now investigating the relationship 
                                                             
319 Axelsson, O. (oskar.axelsson@spagoimaging.se), 12 August, 2009 [e-mail] 
320
 Axelsson, O., personal communication, October 14, 2009 
321 Homepage of The International Center for Nephrogenic Fibrosing Dermopathy Research 
(ICNFDR), NSF – what is it? [Online] 
322 Homepage of The International Center for Nephrogenic Fibrosing Dermopathy Research 
(ICNFDR), NSF – what is it? [Online]  
323 Abu-Alfa, A., Cowper, S., Kanal, E. & Kuo, P., 2007, p. 647 
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between NSF and gadolinium. In the meantime, the FDA advises cautionary use of 
all gadolinium-based contrast agents in patients with renal disease.324 
6.2 Empirics: Market Description 
The overall market for MRI equipment is steadily increasing and is expected to 
reach $3.5 billion by 2012 according to a report by the market research firm 
InMedica, a division of IMS Research of Wellingborough, U.K.325 The United States 
is the largest market among the world's nations and between the year 2000 and 
2005 the number of MRI scanners in the U.S. more than tripled, from 7.6 to 26.6 
machines per million people.326 Other major markets are Western Europe and 
Japan.327 Growing MRI markets are also found in less developed nations in Asia, 
Latin America and Eastern Europe.328  
The number of MRI procedures is also predicted to increase, which strongly 
indicate a growing market for the MRI-contrast agents.  Table 6.1 shows the 
predicted imaging procedures in the United States 2007-2009. 
                                                                     Procedures [millions] 
Modality 2007 2008 2009 
Ultrasound 90.6 101.8 115.1 
SPECT 28.8 32.2 36.3 
MRI 34.1 36.9 39.7 
CT 77.6 87.3 98.6 
PET 1.8 2.1 2.4 
Table 6.1 – Number of U.S. imaging procedures by modality 2007-2009.329 
MRI to screen for breast cancer have also been increasing in recent years and at 
the same time, mammography screening has been decreasing. Nearly 25 % of all 
breast cancer screenings in the United States were done by MRI in 2006, almost 
double the number compared to 2003.330 
An important thing to mention in this context is the 2004 European Commission 
(EC) directive regarding applied electromagnetic fields. This directive 
                                                             
324 Homepage of Doctors Guide, MRI Contrast Agent Linked to Rare Disease [Online]  
325
 Homepage of AuntMinnie.com, Refurbished MRI biggest competition to new systems [Online] 
326 Baker, L. & Baras, J., 2009, p. w1133 
327 Masha, Z., 2002, p. xxii 
328 Freedonia Group, 2004, p. 1 
329 Smith, J., 2005, p. 51 
330 Homepage of Breastcancer.org, New scans prompt mastectomies for breast patients [Online] 
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(2004/40/CE) gives upper limits on applied electromagnetic fields and could 
potentially have a severe impact on the MRI technology. Investigations conducted 
by the EC and the U.K. government concluded that MRI workers routinely exceed 
the exposure limits in the directive, however they didn’t experiences any ill effects 
as a result. This fact led the EC to postpone the directive until April 2012.331 In the 
EU legal system, directives are binding and must be transposed into national 
legislation by all member states.332  
6.3 SWOT Analysis of SPAGO´s Contrast Agent 
6.3.1 Internal Analysis: Strengths and Weaknesses 
The management of SPAGO Imaging AB has to be aware of the advantages and 
disadvantages of their new MRI contrast agent. The overall evaluation of their 
product is therefore presented in form of a SWOT analysis. 
The internal capabilities of the product of SPAGO Imaging AB are identified and 
analyzed. The strengths are internal factors, which can be seen as the competitive 
advantages and the weaknesses can, in the same way, be seen as competitive 
disadvantages. Important to note is that the product is in a development phase 
where the precise data is not completed. The product will, however, not be 
released to the next phase of development until the strengths that are listed 
below have been achieved. 
 
Strengths: 
 Higher contrast 
Not only are there more than thousand of Gadolinium ions in every SPAGO 
particle, where conventional contrast agents have only one, but they also have a 
higher individual efficacy. Hence, SPAGO´s contrast agent gives a higher contrast 
than the conventional contrast agents. This is also leading to a possibility to find 
tumors earlier, when they still is very small. Identifying the tumors early improve 
the probability of a successful treatment. 
 
                                                             
331 Le Bihan, D., 2009, Threats to ultrahigh-field MRI in Europe [Online] 
332 Herbillon, G., 2007, Introduction to the EC Directive 2004/40/CE – Obligations of employers (risk 
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 Selective accumulation in diseased tissue 
One attractive possibility to improve cancer diagnosis is to utilize the optimal size 
of SPACO´s contrast agent to selectively penetrate into tumor tissue, achieving 
passive tumor targeting. This leads to sharper boundaries of the tumor which can 
improve cancer detection and surgery planning. 
 High specificity 
SPAGO´s contrast agent don´t penetrate in to inflammatory tissue, this lead to 
better distinguish between cancerous- and inflammatory tissue. That, together 
with the better contrast and clearer boundaries, strongly indicates that the 
specificity will increase. It will be easier to see if there actually is a tumor or not.  
 Lower dose of contrast agent 
Because SPAGO´s contrast agent only will distribute in approximately 5 liters, 
compared to the commercial contrast agents that has a distribution volume of 50 
liters, the administration dose will be much lower. Lower doses are always 
desirable because of cost and safety reasons. 
 Safe 
Another property of SPAGO´s contrast agent is the safe design. A bioinert and 
durable shell encapsulates and protects the Gadolinium ions from degradation. 
This means that the particles are expected to interfere minimally with normal cells 
and tissues. Furthermore, the size of the intact particle is small enough for being 
entirely excreted through the kidneys out in the urine.  
 Enables Molecular Imaging for cancer diagnostics 
SPAGO´s product is a promising candidate for molecular imaging, but this requires 
development of a new product, meaning new clinical trials. 
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Weaknesses: 
 Small tumors with no vascular tissue 
Small tumors have sometimes not had time to get vascular tissue. The principle of 
selectively penetration into diseased tissue would therefore not work. The 
contrast agent will however still has the basic function as a contrast agent.  
 One-hour waiting period 
It takes up to two hour after the contrast agent has been injected before the 
pictures can be taken. The waiting time is not only disturbing for the patient but it 
can cause organizational problems. 
 New player 
Another weakness that is connected to the company of SPAGO Imaging AB is that 
they are a new player on the market ant therefore not known within this field. 
 
6.3.2 External Analysis: Opportunities and Threats 
This section is based upon data from the analysis of the market environment. The 
opportunities and threats that the product of SPAGO Imaging AB faces from 
outside influences are listed. 
Opportunities: 
 Growing MRI market 
The MRI market in the field of breast cancer is increasing. It may be that more 
doctors and women want the most sensitive test to find early-stage breast cancer, 
even if it means more false positives. Or it could be due to the American Cancer 
Society´s new recommendations to use MRI screening in high-risk women. New 
tools to identify high-risk groups are also being developed (see Appendix C) and 
that will most truly lead to an even greater use of the MRI equipment. 
Since the market of the MRI contrast agents is strongly linked to the MRI market 
will a growing MRI market lead to a more frequent use of MRI-contrast agents 
which is a great opportunity to SPAGO Imaging AB. 
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 Safety issues in non-encapsulated Gd-based contrast agents 
The concern about Nephrogenic Systemic Fibrosis only involve non-encapsulated 
Gd-based contrast agent. Because the SPAGO´s contrast have a bioinert shell that 
encapsulates the Gadolinium ions from degradation can SPAGO´s product actually 
benefit from this discovery. 
 
Threats: 
 New product introduction 
There is always a risk in new products based on an entirely new technology. The 
contrast agent will be the first nanoparticle-based injection preparation on the 
market. Lacking acceptance can therefore be a barrier. On the other hand there is 
an increasing interest for nanomaterial in biomedical applications so that can give 
the product extra publicity. 
 Improved MRI technique 
There is a risk that MRI technology evolves to a degree that most scans can be 
done without contrast agents. Pulse sequences that utilize the effects of contrast 
agents are also being developed and since imaging speed is improved with 
contrast agents it is difficult to predict which way the balance will tip during the 
next few decades. 
 Competition with Customer 
Since SPAGO Imaging AB turns to investors and licensees that already exist in the 
MRI contrast agent market, there may be a risk to compete with their own 
potential customers. One can imagine that these companies do not want to invest 
in SPAGO Imaging AB because it would reduce demand for their own existing 
products.  
 Emergence of new substitutes 
There is always a threat that substitutes with better sensitivity and specificity than 
MRI will be developed. However, since SPAGO's contrast agent enhances the 
existing MRI technology there is no need for new, expensive, equipment. 
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Hospitals certainly prefer a contrast agent that improves the existing technology 
than an entirely new technology that requires buying expensive equipments. 
 
 The European Commission directive 2004/40/CE 
When an MRI scan is being performed most of the staff members leave the room. 
However the main magnet is always on, so when the patient are being placed in 
the scanner or anaesthetized, the staff member is present in the magnetic field. 
Engineers are also exposed to the magnetic field whenever a scanner is being 
installed or serviced. The directive (2004/40/CE) is postponed to April 2012 and it 
is unclear whether the limits will apply to MRI, but if it does, albeit highly unlikely, 
it could end up preventing the technique from being used in Europe. 
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6.4 The Product Life Cycle 
The product of SPAGO Imaging AB is today in a stage before the introduction 
phase, because the product is not yet launched on the market. The nearest stage 
is, however, the introduction phase so the company should start looking at the 
different strategies designed for this phase. 
 
Figure 6.4 – SPAGO´s product is in a stage before the introduction phase,333 
In the introduction phase it is important to create product awareness in the 
customers mind. It is also important to create a non-differentiated product. The 
product that SPAGO Imaging AB now is developing can be said to be non-
differentiated because it can be applied in many different areas. There is an 
opportunity to attach different targeting molecules and create more 
differentiated products, targeted to specific segments, i.e. cancer types. However, 
according to the theory behind the product life cycle, it is good idea to first try to 
launch SPAGO´s original product without targeting molecules because otherwise 
the product becomes too differentiated and a too narrow market is created. 
There are two well-known strategy options in the introduction phase: skimming or 
penetrating. Because of the high development costs and because high entry 
barriers exist (due to existing/future patent) I suggest the skimming strategy. The 
price of the product should therefore be relatively high. 
                                                             
333 Homepage of NoteDesk, The product life cycle [Online] (Redrawn) 
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6.5 The Ansoff Matrix 
Since SPAGO´s contrast agent is a new product and it will be launched on an 
already existing market (MRI for breast cancer) it can therefore be said to be a 
product development. 
 
Figure 6.5 – The diversification strategy. 
According to the theory there were three different way to conduct a product 
development: product extension, product replacement or product innovation. The 
product of SPAGO Imaging AB is based on a whole new technology and is 
therefore a product innovation. There were two different approaches for 
innovation: technology push or market pull. Because the product is entirely based 
on the knowledge created by the scientists at SPAGO Imaging AB, the approach 
can said to be a technology push. 
One important thing regarding the technology push approach is to not lose the 
customer focus. The history is filled with examples of companies that have blindly 
pursued technological developments without regard to the real market needs. 
Therefore it is important that the company analyze the customers; who there are, 
their needs and their preferences, to maintain a customer focus. 
  
74 
 
 
  
75 
 
7. Summary and Reflections 
 
Chapter seven summarizes the impressions from the empirics and the analysis. The 
most important findings are brought together and form the basis of the presented 
recommendations for SPAGO Imaging AB.  
 
The purpose of this thesis was to analyze the market of SPAGO Imaging AB´s 
product in the field of breast cancer. Both an analysis of the different methods 
used to screen and diagnose breast cancer and an analysis of SPAGO´s contrast 
agent was conducted.  
The study has shown that mammography is the common method for screening 
the general population. The method is sometimes complemented with Breast 
Physical Examination to first see if any suspicious nodules can be found. For 
women with dense breast or when needing a second screening test, either 
sonography or MRI are used.  
 
MRI is a powerful tool for finding signs of breast cancer because of its high 
sensitivity, but, as the analysis shows, the modality also has downsides in the form 
of a relatively high false-positive rate and the high cost per scan.  Therefore, MRI 
is not appropriate as a screening test for the general population. 
We are, however, likely to transition from a standardized screening, where all 
women undergo the same screening examination, i.e. mammography, to selection 
of a screening modality based on individual-risk. Women with increased risk need 
a more sensitive detection tool and because the MRI is the most sensitive 
screening method that exists today is the method also being recommended by the 
ACS.  
 
Regarding the methods that are used to diagnose breast cancer, they can be said 
to have two different purposes. One purpose is to classify the tumor, to see if it’s 
benign or malignant. For this role is biopsy the best method and no non-invasive 
test can compete with it today. 
 
The other purpose of a diagnostic test is to determine size and location of the 
tumor and to see whether or not it has spread to the lymph nodes. For this 
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purpose mammography and sometimes sonography are being used, despite the 
fact that MRI probably would be a better alternative. Why MRI isn’t used instead 
can be due to the low specificity or simply because it’s a relatively new method 
and the advantages have not yet been recognized. However, MRI will certainly 
play an increasingly important role in the diagnosis of patients with breast cancer. 
 
I believe that the use of SPAGO´s contrast agent, to obtain improved MR-images, 
will also play a great role for the increased utility of the MRI technology. The 
product will probably increase booth the sensitivity and the specificity of the MRI 
method. 
The product will however not change the fact that the MRI is not appropriate for 
general screening, despite the fact that the specificity will increase. The reason 
the high cost together with the long waiting time after the administration of the 
contrast. 
The potential market segments of SPAGO´s contrast agent is instead risk-group 
screening. It will be easier to find the women with increased risk as new and 
better tools are being developed and for these women the sensitivity of the test is 
the most important factor regarding screening tests. The MRI technology together 
with SPAGO´s new contrast agent will give a high sensitivity and therefore will 
more tumors be found in an early phase, leading to that more lives can be saved. 
SPAGO´s contrast agent will also increase the otherwise relatively low specificity, 
so that fewer people will be misdiagnosed. The products high cost would probably 
not create any major problem because earlier detection also means cheaper 
treatments.  
As mentioned earlier, the MRI will play an increasingly important role in the 
diagnostics area, so this market segment is also very attractive. SPAGO´s contrast 
agent will give better images, so the exact location, size and shape can be 
determined in higher extent.  
The most important opportunity, identified in the SWOT analysis, is the growing 
MRI market in the field of breast cancer. A growing MRI market leads to a more 
frequent use of MRI-contrast agents, which is a great opportunity to SPAGO 
Imaging AB. The most important threat is the fact that SPAGO´s contrast agent is 
nanoparticle-based, actually the first injection preparation based on nano-science. 
There is always a risk in new products based on an entirely new technologies, 
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lacking acceptance can therefore be a barrier. Therefore, it is important that the 
company clearly emphasizes the product's high safety. 
An important opportunity is the ability to attach targeting molecules on the 
particles, creating what is referred to as molecular imaging. A contrast agent with 
a targeting function would probably have very high sensitivity and specificity and 
according to Christer Lundahl the price of such product could allows being very 
high, 20 000kr/dose (see Appendix D).334 The ability to develop contrast agents 
with targeting functions from the platform technology will itself be a good selling 
point.  Therefore, I believe that it is important for the company to point out this 
opportunity for potential investors. 
Recommended future studies regarding marketing research for SPAGO´s contrast 
agent could be another cancer type, such as prostate cancer. Prostate cancer is 
the second most frequently diagnosed cancer in men and screening tests for this 
malignancy is today a hot topic, with different clinical trials taking place in many 
parts of the world. So there is a major potential that the MRI technology together 
with SPAGO´s contrast agent could be used as a prostate cancer screening test.  
 
Another interesting application area could be pancreatic cancer. At present, there 
is no method for the early detection of this sort of cancer. Therefore are the 5-
year relative survival rates only 5 %. Research is underway to identify better 
methods of early detection and MRI together with SPAGO´s contrast agent could 
perhaps be an option. 
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Appendix A – The Questionnaire 
 
1. När används MRI idag när det gäller bröstcancer? 
2. Vad tycker Ni det finns för fördelar och nackdelar med MRI? 
3. Finns det några problem/nackdelar idag med de kontrastmedel för MRI 
som finns ute på marknaden? 
4. Vilka önskemål har Ni gällande nya kontrastmedel inom MRI? 
Nedanför beskrivs tre olika kontrastmedel (P1, P2 och p3). Läs igenom dessa 
produktbeskrivningar och svara sedan på frågorna 5-6. 
P1 
Pris = 200 kr/ dos 
Säkerhet = 1 % risk för allvarlig biverkning* gfr<60 mL/min/1.73m2 
Sensitivitet= tumörer > 5mm 90 % 
Specificitet= tumörer > 5mm 70 % 
 
P2 
Pris = 3000 kr/ dos 
Säkerhet = 1 % risk för allvarlig biverkning* gfr<60 mL/min/1.73m2 
Sensitivitet= tumörer > 2mm 90 % 
Specificitet= tumörer > 2mm 90 % 
P3 
Pris = 20 000 kr/ dos 
Säkerhet = <1 % risk för allvarlig biverkning* gfr<60 mL/min/1.73m2 
Sensitivitet= tumörer > 2mm 95 % (30 % subgrupp ty HER2 typ allvarlig) 
*Allvarlig biverkning betyder behov av sjukhusvistelse. 
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5. Vilket kontrastmedel skulle du ge till följande patientgrupp och varför? 
 
a) Populations screening (kvinnor mellan 50 och 69 år)          
     
      P1              P2                P3 
 
b) Unga kvinnor med kompakt bröstvävnad                 
                  
      P1              P2                P3 
                                  
c) Kvinnor som har en släkting av första generationen (mor, syster, dotter)  
som har/haft bröstcancer                   
              
   P1              P2                P3 
 
d) Kvinnor som har haft bröstcancer tidigare                
 
     P1              P2                P3 
 
e) Kvinnor som enligt genetisk profilering har  25 % eller högre ökad risk för 
bröstcancer             
 
     P1              P2                P3 
 
f) Kvinnor 70 år och äldre        
              
      P1              P2                P3 
 
6. Är det någon av dessa tre kontrastmedel som skulle göra att användandet 
av kontrastmedel skulle öka och i så fall varför? 
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Appendix B – Explanation of the Concepts Sensitivity and 
Specificity 
Consider a test that only has two outcomes; positive or negative. Four possible 
scenarios can then occur. 
 
Sensitivity represents the proportion of truly diseased persons in a population 
who are identified as being diseased by the test. It is a measure of the probability 
of correctly diagnosing a condition. Sensitivity is calculated as follows:335  
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑇𝑟𝑢𝑒₋𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒₋𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠  +  𝐹𝑎𝑙𝑠𝑒₋𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
 =  
𝑎 
𝑎 + 𝑐
 
Specificity of a test is defined as the percentage of persons without the disease of 
interest who have negative test results. It is a measure of the probability of 
correctly identifying a non-diseased person. Specificity is calculated as follows:336  
 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =  
𝑇𝑟𝑢𝑒₋𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒₋𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠  +  𝐹𝑎𝑙𝑠𝑒₋𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 =  
𝑑
𝑑 + 𝑏
 
 
                                                             
335 Last, J., Porta, M., 2008, p. 227 
336 Last, J., Porta, M., 2008, p. 227 
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Besides worrying about being diagnosed with breast cancer, a false positive 
means more tests and follow-up visits, which can cause psychological stress and 
anxiety.337 False negatives cause critical delays in diagnosis and treatment.338  
  
                                                             
337 Affleck, I., Cordiner, C., Gilbert, F., Hood, D., Mathieson, D. & Walker, L., 1998, p. 2010 
338 Lister-Sharp, D., Petticrew, M. & Sowden, A., 2001, p. 164 
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Appendix C – Future Techniques for Breast Cancer 
Detection 
A complemented analysis of future techniques for breast cancer detection has 
been conducted. Segmentation of the future techniques has been conducted in 
the same way as for the current techniques. The techniques have been divided 
into two segments: screening tests and diagnostic tests. 
Segment Tests 
Screening tests Speed-Weighted 3-D Power Doppler Ultrasound 
Hair Sample 
Saliva 
Cone Beam Breast Computed Tomography scanner 
Risk prediction tools 
Diagnostic tests Breast PET/CT Scanner 
PET/MRI Hybrid 
Tumor Markers 
 
 
Screening Tests 
Speed-Weighted 3-D Power Doppler Ultrasound 
Sonography plays an important role in the assessment of suspect lesions viewed 
on mammograms. However, the accuracy of the technique is limited due to the 
significant number of false-positive results. The Speed-weighted 3-D power 
Doppler ultrasound represents a novel approach for more accurate detection of 
breast cancer. The method gives three-dimensional pictures of the breast and 
enables evaluation of breast tumor blood flow, analysis of the distribution of 
blood vessels, and quantitative measurement of blood flow velocity waveforms. A 
study with 78 women shows that the method has 100% sensitivity and 86% 
specificity.339  
The Speed-weighted 3-D power Doppler ultrasound is launched on the market, 
but so far the product is not fully accepted, probably because of the lack of 
studies to ensure the technology's ability. Only one study has been conducted and 
it showed both high sensitivity and high specificity. The study was however very 
                                                             
339 Carson, P., Engle, K., Fowlkes, B., Hunt, K., Johnson, T., Krücker, J., LeCarpentier, G., Paramagul, 
C., Roubidoux, M. & Thorson, N., 2008,  pp. 463-470 
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small, so further evaluations are necessary to determine the correct values. It is 
difficult to comment on how the future of the technology will be without knowing 
the methods´ accuracy, but it will probably take over the role of Sonography, 
namely to screen young women with dense breasts. 
 
Hair Sample 
Scientists think that breast cancer might change hair's chemistry or the hair's 
follicle. A small study suggests that a special type of x-ray test (alpha-keratin 
diffraction pattern) done on hair found a unique ring pattern in the hair of women 
with breast cancer. However, the x-ray test wasn't perfect. One woman (out of 
13) diagnosed with breast cancer didn't have the ring pattern in her hair and three 
women (out of 20) who didn't have breast cancer did have the ring pattern in 
their hair.340  
The hair sample method is probably cheaper (per scan) than the existing 
techniques used today, but since the technology has both low sensitivity and 
specificity it´s highly unlikely that the method will be used in any large extent.  
 
Saliva 
Scientists in the United States are developing a screening test for breast cancer 
that checks a woman's saliva for evidence of the disease. They have identified 49 
proteins in saliva that the screening test would track to distinguish healthy 
women from those with breast cancer. The focus is to launch the product as a 
screening tool in developing countries because mammograms are too expensive 
in these markets. The product is still in a development stage and no values for 
sensitivity and specificity are available.341 
The saliva method is also unlikely to pose any threat to the existing screening 
methods, because it is not likely that the test will get accurate sensitivity and 
specificity parameters. The method will especially not be a threat to the MRI 
technology, because it is directed to those markets that cannot afford the MRI 
equipment. 
                                                             
340 Corino, G. & French, P., 2008, p. 847 
341 Dunham, W., 2008, [Online] 
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Cone Beam Breast Computed Tomography Scanner 
The Cone Beam Breast Computed Tomography scanner is a new kind of test to 
screen for breast cancer. Researchers believe that this new breast imaging 
technique will make breast cancers easier to see in dense breast tissue and will 
make breast screening more comfortable.  The cost will be significantly more than 
a traditional mammogram. Right now, the Cone Beam system is available only for 
research purposes so no values for sensitivity and specificity are available.342 
It is difficult to evaluate the Cone Beam Breast Computed Tomography scanner 
because it is in an early development phase where no data of sensitivity or 
specificity is available. One major drawback is that the technique will have a high 
cost. 
 
Risk Prediction Tool 
Risk prediction tools are not screening test, they do not detect cancer, but they 
can be said to belong to the category any way. The function of the tests is to find 
individuals at high risk for developing breast cancer so that these people get their 
screening tests more often and maybe get screened with more sensitive tests. 
Today there are a few tools available to evaluate a person's risk of developing 
cancer. One test is the Gail model. The Gail model uses a woman's own personal 
medical history (number of previous breast biopsies and the presence of atypical 
hyperplasia in any previous breast biopsy tissue), her own reproductive history 
(age at the start of menstruation and age at the first live birth of a child) and the 
history of breast cancer among her first-degree relatives to estimate her specific 
risk of developing breast cancer.343 
Scientists at the University of Toronto have also developed a new technique based 
on digital micro fluidics, where tiny droplets of fluid are manipulated electrically 
on the surface of a microchip. The technique measure the Estrogen level, which is 
a key hormone in human reproductive physiology, controlling ovulation and 
secondary sexual characteristics. The concentration of Estrogen and its 
                                                             
342 Homepage of Breastcancer.org, Scan could do away with mammogram pain [Online] 
343 Homepage of National Cancer Institute, About the tool [Online] 
104 
 
metabolites in breast tissue are known to be increased in breast cancer patients 
compared to healthy women.344 
 
Diagnostic Tests 
Breast PET/CT Scanner 
Researchers from the University of California, Davis (UCD) have constructed a 
dedicated breast PET/CT scanner, which will combine the sensitivity of PET 
imaging with the anatomical localization capabilities of CT.345,346 The device is fully 
three-dimensional. Therefore, the method doesn’t have the shadowing problem 
of 2D images. Shadowing can be problematic with mammography in patients with 
breast implants, because the implant will cover the cancer and make it difficult to 
visualize. Only four women have been imaged so the sensitivity and specificity 
could not be analyzed.347  
 
The breast PET/CT scanner is expected to have a high sensitivity and specificity. 
The method also exposes the patient to a large dose of radiation and probably has 
a significantly high cost. Because of these drawbacks, the method is unlikely to 
pose any major threat to the existing diagnostic tests.  
 
PET/MRI Hybrid 
Researchers at Stony Brook University in New York are working to develop a high-
resolution PET imaging system that can work inside an MRI scanner.  The goal is to 
combining the MRI's high-resolution anatomic images with quantitative 
biochemical information from PET. The combination of these two pieces will, 
according to Bosky Ravindranath, research assistant and lead author of a study, 
lead to better diagnosis, staging and evaluation of breast cancer. A prototype has 
                                                             
344
 Abdelgawad, M., Casper, R., Chen, J., Jebrail, M., Metalnikov, P., Mousa, N., Wheeler, A., & Yang, 
H., 2009, p. 1ra2 
345 Badawi, R., Boone, J., Borowsky, A., Bowen, S., Burkett, G., Chaudhari, A., Cherry, S.,  Fu, L., 
Hagge, R., Lindfors, K., Martinez, S., Packard, N., Qi, J., Shelton, D., Wu, Y. & Yang, K., 2009, pp. 1401-
1408 
346 Benard, F. & Turcotte, E., 2005, p. 154 
347 Badawi, R., Boone, J., Borowsky, A., Bowen, S., Burkett, G., Chaudhari, A., Cherry, S.,  Fu, L., 
Hagge, R., Lindfors, K., Martinez, S., Packard, N., Qi, J., Shelton, D., Wu, Y. & Yang, K., 2009, pp. 1401-
1408 
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been built, but it´s only for rats because the prototype has an inner diameter of 
145 mm and an axial length of 96 mm.348  
The new PET/MRI technology is at a very early stage of development so how 
accurate the method will be in the end is difficult to say. The method is a threat to 
the traditional MRI technique but is not necessarily a bad thing for SPAGO Imaging 
AB, because it is possible that the new method also need contrast agents. 
 
Tumor Markers 
Researchers are starting to focus on genetic markers to detect cancer. Most 
cancers have changes in their DNA, so by looking for DNA changes in blood, stool 
or urine, scientists may be able to find cancers very early. The study of patterns of 
DNA changes (known as genomics) is likely to prove more useful than looking for 
single DNA changes. This new testing methods are still in the early stages of 
development. 349 
Another new approach is called proteomics. This technology looks at the patterns 
of all the proteins in the blood instead of looking at individual protein levels. Two 
blood tests have already been developed, Oncotype DX™ and MammaPrint®.350  
The Oncotype DX test analyzes 21 specific genes in breast tumor sample. The test 
can predict the likelihood that invasive breast cancer will return or if the patient 
would benefit from chemotherapy.351, 352 The test results in a so called Recurrence 
Score, a number between 0 and 100 that shows the risk of the breast cancer 
returning within 10 years of the original diagnosis. If the Recurrence Score are 18 
or less the risk is said to be low, if the score is 31 or more the risk is high and if the 
score is 19 to 30 then the recurrence risk is said to be intermediate.353  
The MammaPrint measures the activity of 70 genes. The test accurately picked 
which women were at low risk at least 90 percent of the time. Conversely, for 
                                                             
348 Forrest, W., 2009, PET/MRI breast imaging prototype shows early promise, AuntMinnie, June 16 
[Online] 
349 Homepage of American Cancer Society, Tumor markers [Online] 
350 Homepage of American Cancer Society, Tumor Markers [Online]  
351 Homepage of Breastcancer.org, Oncotype DX Test [Online]  
352 Homepage of WebMD, Oncotype DX Test for Breast Cancer [Online] 
353 Homepage of WebMD, Oncotype DX Test for Breast Cancer [Online] 
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women who were told they were at high risk for a recurrence within five years, 
just 23 percent actually had their cancer come back.354 
Both of these tests are relatively new and have been tested on relatively small 
groups of women. Both tests cost more than $3,000.355  
The proteomics method is an interesting future technique. Research and 
development are in progress, but the tests that are available today (Oncotype 
DX™ and MammaPrint®) are both too expensive and have too many false positive 
to really pose any threat to the existing diagnostic methods.  
 
 
 
 
 
 
 
 
 
 
 
                                                             
354 Richwine, L., 2007, U.S. OKs test to predict breast cancer return, Breastcancer.org [Online] 
355 Kahn, M., 2007, Simple test may help predict breast cancer return, Breastcancer.org [Online]  
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Appendix D – Interview with Christer Lundahl, 2009-10-
06 
 
Vad finns det för fördelar och nackdelar med MRI? 
 MRI är överlägsen jämfört med CT och konventionell röntgen när det 
gäller mjukvävnad. Mycket känsligare när det gäller att differentiera 
vävnad.  
 MRI innebär ingen röntgenstrålning.  
 Man kan eftergranska. Det kan man inte med ultraljud på samma sätt. 
 Man kan använda tekniken på unga kvinnor (ju yngre kvinnor ju tätare 
bröst). Mammografi fungerar inte lika bra på täta bröst. 
 
 MRI är dyrare och tar längre tid än mammografi. 
 MRI är inte bra på kalk, det är däremot mammografi bra på. 
 Organisatoriskt svårt att screena eftersom injektion av kontrastmedel 
måste ske innan MRI.  
När används MR idag när det gäller bröstcancer? 
 Används i unga patienter då deras bröst har en hög täthet av körtelvävnad 
jämfört med äldre kvinnor. 
 Används när man konstaterat ärftlig bröstcancer. 
Annars används mammografi och ultraljud + biopsi. 
Utomlands händer det mycket med MRI. I Sverige är det frågan om en 
generationsväxling. Radiologer inom området mammografi är hittills inte lika 
flitiga användare av MRI. 
P1, P2 & P3 
På unga kvinnor skulle valet vara P3, om produkten når upp till sensitivitets- och 
selektivitetsnivåerna. Unga kvinnor med bröstcancer har stor risk för att dö, då 
har priset för kontrastmedel ingen avgörande betydelse.  
För allmän screening skulle valet vara P1 på grund av priset. Det som är allra 
viktigast vid allmän screening är säkerheten.  
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För andra riskgrupper än unga kvinnor skulle valet antingen vara P2 eller P3. En 
fråga om nytta kontra kostnaden. Samhällsekonomisk fråga. Är det värt ett högre 
pris? 
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Appendix E – Interview with Katarina Rönnow, 2009-11-
16 
 
När används MRI idag när det gäller bröstcancer? 
Okänd primärtumör vid axillmetastas. Resultat av cytostatikaterapi. Vid icke 
synliga tumörer på mammografi; ev. multifokalitet. För att se om misstänkt 
vävnad är ärrvävnad eller en ny tumör. Hereditetsstudier. Local staging 
preoperativt: storlek och för att undersöka det kontralaterala bröstet. 
Vad tycker Ni det finns för fördelar och nackdelar med MRI? 
 Hög sensitivitet (fördel).   
 Låg specificitet (nackdel).  
 
 Ganska dyr undersökning.  
 Svårt att få tillräckligt med tid på de MR-maskinerna vi har. 
Finns det några problem/nackdelar idag med de kontrastmedel för MRI som 
finns ute på marknaden? 
Vi har Dotarem 4 ml/kg. VI har inte haft några bekymmer, men vi utför tyvärr bara 
en undersökning/vecka.  
Vilka önskemål har Ni gällande nya kontrastmedel inom MRI? 
 Bättre specificitet. Inte så dyra. Ingen allergi. 
Är det någon av dessa tre kontrastmedel som skulle göra att användandet av 
kontrastmedel skulle öka och i så fall varför? 
Kostnaden på 20000kr för en undersökning är för mycket. Man kommer att 
använda sig av de andra i första hand för en ”screening” och utifrån den 
undersökningen gå vidare med dyrare kontrastmedel och andra undersökningar. 
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Appendix F – Interview with Axel Johansson, 2009-11-16 
 
När används MRI idag när det gäller bröstcancer? 
Där jag jobbar på Ängelholms Sjukhus använder vi bara MRI vid frågeställning 
metastaser till lever, hjärna och skelett från bröstcancer. 
Vad tycker Ni det finns för fördelar och nackdelar med MRI? 
 Ingen röntgenstrålning. 
 När det gäller frågeställningen skelettmetastaser är fördelen att stor del 
av skelettet kan undersökas, tidiga metastaser som inte orsakat 
skelettpåverkan kan detekteras och man kan oftast skilja på metastas och 
degenerativa förändringar i skelettet. 
 
 Negativt med lång undersökningstid, känsligt för rörelseartefakter, man 
kan inte ha pacemaker, smärtstimulatorer och liknande inopererade 
elektroder. 
  
Finns det några problem/nackdelar idag med de kontrastmedel för MRI som 
finns ute på marknaden? 
Risk för Nefrogen Systemisk Skleros samt att de är njurtoxiska. 
Vilka önskemål har Ni gällande nya kontrastmedel inom MRI? 
Patienterna ska tåla dessa. De ska inte vara allergena eller giftiga och de ska ge 
snabb effekt. 
De ska vara lätta att administrera i förfyllda sprutor i rumstemperatur. 
P1, P2 & P3 
För populationsscreening skulle valet vara P3. Om man vet att 1 % får läggas in på 
sjukhus p.g.a. kontrasten för medel 1 och 2 vilket blir ca 5000 personer varje år så 
måste man ju ta det medlet med minst biverkningar. Screening vartannat år i 20 
år av 50000 kvinnor per årsklass. Biverkningsprofilen vid screening viktig då 
många patienter ska utsättas för medlet. 
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P3 skulle även väljas för kvinnor som har 25 % eller mer ökad risk för bröstcancer. 
Detta eftersom en hög sensitivitet krävs. 
För unga kvinnor skulle valet vara P2 då bra specificitet krävs. För kvinnor med 
förstagradssläktingar med bröstcancerhistorik och för kvinnor som har haft 
bröstcancer tidigare skulle valet vara P2, då bra sensitivitet och specificitet krävs.  
För kvinnor över 70 år skulle P1 väljas. Inte så många patienter kommer ifråga och 
tumörerna är stora. 
Är det någon av dessa tre kontrastmedel som skulle göra att användandet av 
kontrastmedel skulle öka och i så fall varför? 
Ja, P3, eftersom biverkningsprofilen är så liten jämfört med övriga – viktigt då man 
undersöker friska så att man inte orsakar sjukdom genom 
undersökningsmetoden. 
 
 
 
